A 52-year-old man presents with a 1-month history of a depressed mood. He says that he has been “feeling low” on most days of the week. He also says he has been having difficulty sleeping, feelings of being worthless, difficulty performing at work, and decreased interest in reading books (his hobby). He has no significant past medical history. The patient denies any history of smoking, alcohol use, or recreational drug use. A review of systems is significant for a 7% unintentional weight gain over the past month. The patient is afebrile and his vital signs are within normal limits. A physical examination is unremarkable. The patient is prescribed sertraline 50 mg daily. On follow-up 4 weeks later, the patient says he is slightly improved but is still not feeling 100%. Which of the following is the best next step in the management of this patient?
A 27-year-old man presents to his physician for a checkup. At presentation, he complains of anxiety and persistent mood changes. The patient's comorbidities include chronic gastritis treated with Helicobacter pylori eradication therapy, and chronic pyelonephritis with stage 1 chronic kidney disease. His grandfather who was a heavy smoker just passed away due to metastatic lung cancer. The patient has an 8-year-history of smoking, and he is concerned about consequences of his habit. He says that he tried to quit several times with nicotine patches, but he is unsuccessful because of the unpleasant symptoms and returning anxiety. Moreover, his tobacco use increased for the past 12 months due to increased anxiety due to his job and family problems, which could not be relieved by previous consumption levels. He still wants to stop smoking due to the health concerns. The patient's vital signs and physical examination are unremarkable. The physician considers prescribing the patient a partial nicotine agonist, and conducts a further testing to see whether the patient is eligible for this medication. Which of the following tests is required to be performed prior to prescribing this medication to the presented patient?
A 50-year-old woman presents to her family physician 6 months after the death of her husband, who died following a car accident. She is crying inconsolably and reports that she no longer enjoys doing the things she and her husband once did together. She feels guilty for the time she wasted arguing with him in the past. She finds herself sleeping on most mornings, but still lacks the energy and concentration needed at work. The physical examination is normal. Based on a well-known hypothesis, which of the following combinations of neurotransmitter abnormalities most likely exist in this patient?
A 43-year-old woman is brought to the physician by her daughter because she has been intermittently crying for 6 hours and does not want to get out of bed. Her symptoms started after she was fired yesterday from her job of 20 years. She says she feels sad and does not understand what she will do with her life now. She uses an over-the-counter inhaler as needed for exercise-induced asthma, and recently started oral isotretinoin for acne. She used to smoke a pack of cigarettes per day, but for the last year she has decreased to 2 cigarettes daily. She appears sad and very upset. Her temperature is 37°C (98.6°F), pulse is 110/min, respirations are 20/min, and blood pressure is 140/80 mm Hg. Physical examination shows no other abnormalities. On mental status examination, she is oriented to person, place, and time. She maintains eye contact and follows instructions. She denies suicidal ideation. Which of the following is the most likely explanation for this finding?
A 22-year-old female presents to your clinic for evaluation of "skin problems." She complains of severe acne and "spots" all over her face that have persisted for the last 8 years, despite innumerable creams and lotions. She reports spending several hours every morning using make-up just to go outside. She wishes to learn about cosmetic procedures or surgeries that could solve her problem. While you perceive her concern for her skin to be genuine, upon examination, you note a healthy-appearing, well-nourished female with a normal complexion, minimal acne and sparse freckles on the nasal bridge. You calculate her BMI to be 21. In addition to making a diagnosis, this patient should be screened for which other disorder?
A 69-year-old woman presents to the clinic with one week of suicidal ideation. She has a history of depression that began after her husband passed away from a motor vehicle accident seven years ago. At the time, she attempted to overdose on over-the-counter pills, but was able to recover completely. Her depression had been adequately controlled on sertraline until this past week. Aside from her depression, she has a history of hypertension, which is controlled with hydrochlorothiazide. The patient is retired and lives alone. She spends her time gardening and is involved with her local community center. On further questioning, the patient states that she does not have an organized plan, but reveals that she did purchase a gun two years ago. She denies tobacco, alcohol, or illicit substances. Which of the following is this patient’s most significant risk factor for completed suicide?
A 22-year-old college student comes to the physician because of depressed mood and fatigue for the past 5 weeks. He has been feeling sad and unmotivated to attend his college classes. He finds it particularly difficult to get out of bed in the morning. He has difficulty concentrating during lectures and often feels that he is less intelligent compared to his classmates. In elementary school, he was diagnosed with attention deficit hyperactivity disorder and treated with methylphenidate; he stopped taking this medication 4 years ago because his symptoms had improved during high school. He has smoked two packs of cigarettes daily for 8 years; he feels guilty that he has been unable to quit despite numerous attempts. During his last attempt 3 weeks ago, he experienced increased appetite and subsequently gained 3 kg (6 lb 10 oz) in a week. Mental status examination shows psychomotor retardation and restricted affect. There is no evidence of suicidal ideation. Which of the following is the most appropriate pharmacotherapy?
A 42-year-old female presents to her primary care provider for an annual checkup. She reports feeling sad over the past few months for no apparent reason. She has lost interest in swimming, which she previously found enjoyable. Additionally, she has had trouble getting a full night’s sleep and has had trouble concentrating during the day. She has lost 15 pounds since her last visit one year prior. Which of the following sets of neurotransmitter levels is associated with this patient’s condition?
A 35-year-old banker is brought to a medical clinic by his concerned wife. For the past 3 weeks, he has not been eating well and has had a 10 kg (22 lb) weight loss. He wakes up very early in the mornings and feels extremely despondent. He no longer goes out on the weekends to hang out with his close friends nor does he go on date nights with his wife. He feels guilty for letting his friends and family down recently. He additionally has a history of fibromyalgia and deals with daily pain. What would be the most appropriate treatment plan for this patient?
A 28-year-old woman presents with depressed mood lasting for most days of the week for the past month. She also mentions that she has lost her appetite for the past 3 weeks. She adds that her job performance has significantly deteriorated because of these symptoms, and she feels like she will have to quit her job soon. Upon asking about her hobbies, she says that she used to enjoy dancing and music but does not have any desire to do them anymore. The patient’s husband says that she has had many sleepless nights last month. The patient denies any history of smoking, alcohol intake, or use of illicit substances. No significant past medical history. Physical examination is unremarkable. Routine laboratory tests are all within normal limits. Which of the following clinical features must be present, in addition to this patient’s current symptoms, to confirm the diagnosis of a major depressive episode?
Explanation: ***Continue sertraline*** - Many antidepressants, including SSRIs like sertraline, require **4-6 weeks at a therapeutic dose** to achieve their full effect. Since the patient reports slight improvement after 4 weeks, continuing the current medication allows more time for optimal response. - The goal is for the patient to feel "100%", which often takes longer than one month. **Gradual improvement** after initial therapy suggests the medication is working, but needs more time. *Switch to a different SSRI* - Switching to another SSRI is typically considered if there is **no improvement or significant intolerance** after an adequate trial (at least 4-6 weeks) at a therapeutic dose of the initial SSRI. - This patient has shown *slight improvement*, indicating that sertraline may still be effective with more time. *Add buspirone* - Buspirone is an **anxiolytic medication** sometimes used as an augmentation strategy for depression, particularly if anxiety is a prominent symptom. - However, it's generally added *after* an initial antidepressant has failed to achieve a full response, and typically *after* optimizing the dose and duration of the primary antidepressant. *Switch to an MAOI* - **Monoamine oxidase inhibitors (MAOIs)** are older antidepressants with a more challenging side effect profile and significant drug-drug and drug-food interactions. - They are typically reserved for patients who have **failed multiple trials of other antidepressants** due to their safety concerns. *Add aripiprazole* - Aripiprazole, an **atypical antipsychotic**, is sometimes used as an augmentation strategy for **treatment-resistant depression**. - This approach is usually considered when trials of several different antidepressant classes have failed or when the depression has not responded adequately to optimized antidepressant therapy.
Explanation: ***9-item patient health questionnaire*** - This patient is on a **partial nicotine agonist** (likely **varenicline**) and has a history of anxiety, mood changes, and chronic kidney disease, which requires a psychiatric assessment. - Varenicline has been associated with **neuropsychiatric effects**, including mood changes and suicidal ideation, making baseline assessment of mental health crucial. *Echocardiography* - This test is primarily used to assess **cardiac function** and structure. - Although smoking is a risk factor for cardiovascular disease, there is no indication for an echocardiogram based on the patient's current symptoms or the intended medication. *Creatinine assessment* - While the patient has **stage 1 chronic kidney disease**, the medication in question (varenicline) is primarily renally cleared. A **creatinine assessment** would be relevant for dose adjustment, but it is not typically a prerequisite for *eligibility* itself since the medication can be used in patients with kidney disease with dose modification. - The medication can be used but usually needs **dose adjustments** for patients with kidney impairment (creatinine clearance below 30 mL/min); therefore, it is often done, but mainly for dose modification, not for eligibility given stage 1 CKD. *Esophagogastroduodenoscopy* - This procedure is relevant for evaluating the upper gastrointestinal tract and is indicated for conditions like **chronic gastritis** or suspected peptic ulcer disease. - While the patient has a history of chronic gastritis, there is no current indication for an EGD related to the intended **smoking cessation medication.** *Mini mental state examination* - The **MMSE** assesses **global cognitive function** and screens for conditions like dementia. - The patient's symptoms of anxiety and mood changes do not primarily suggest cognitive impairment, and a psychiatric questionnaire is more appropriate for evaluating his specific mental health concerns.
Explanation: ***↓ Norepinephrine, ↓ Serotonin, ↓ Dopamine*** - The patient's symptoms (anhedonia, guilt, fatigue, poor concentration, sleep disturbance) are classic for **major depressive disorder**. - According to the **monoamine hypothesis of depression**, an imbalance of monoamine neurotransmitters (norepinephrine, serotonin, and dopamine) is implicated, with a **decrease** in their levels or activity leading to depressive symptoms. *↑ Norepinephrine, ↑ Serotonin, ↑ Dopamine* - **Elevated levels** of these neurotransmitters are typically associated with conditions like **mania** or **anxiety disorders**, not depression. - This pattern would lead to increased energy, euphoria, or agitation, which are contrary to the patient's presentation. *Normal Norepinephrine, ↓ Serotonin, Normal Dopamine* - While **decreased serotonin** is a key component of the monoamine hypothesis of depression and often targeted by SSRIs, depression typically involves a broader dysregulation of monoamines. - The patient's significant symptoms of fatigue and lack of concentration also suggest involvement of **norepinephrine** and **dopamine** deficiencies. *Normal Norepinephrine, Normal Serotonin, ↑ Dopamine* - An **increase in dopamine** is generally associated with conditions like **psychosis** or **reward-seeking behavior**, and would not explain the patient's anhedonia and low energy. - Normal levels of serotonin and norepinephrine would also not fully account for the scope of the patient's depressive symptoms. *Normal Norepinephrine, Normal Serotonin, ↓ Dopamine* - While **decreased dopamine** can contribute to anhedonia and lack of motivation, a diagnosis of major depressive disorder, especially with guilt and severe fatigue, is typically linked to a more widespread deficiency in *all three monoamines*. - Normal levels of norepinephrine and serotonin would be unlikely given the severity and range of the patient's depressive symptoms.
Explanation: ***Normal stress reaction*** - The patient's symptoms (crying, sadness, not wanting to get out of bed) are a direct, understandable emotional response to a significant recent stressor (being fired from a 20-year job). This type of reaction is **expected and transient** in response to acute life changes. - The duration of symptoms is short (6 hours), and there is **no evidence of significant functional impairment** beyond the initial emotional distress, nor does she meet criteria for a mental disorder. *Drug-related depression* - While **isotretinoin has been associated with mood changes**, including depression, the acute onset and direct temporal relationship to a significant psychosocial stressor make a drug-related cause less likely as the primary explanation. - There are no other features pointing to drug-induced etiology, and her symptoms are clearly linked to the job loss. *Acute stress disorder* - Acute stress disorder symptoms (e.g., intrusive thoughts, negative mood, dissociation, avoidance, arousal) typically involve exposure to an **actual or threatened traumatic event**, such as death or serious injury, which is not the case here. - The symptom duration for acute stress disorder is also typically 3 days to 1 month, and the patient's symptoms are of much shorter duration and less severe. *Adjustment disorder* - Adjustment disorder involves significant emotional or behavioral symptoms in response to an identifiable stressor, but these symptoms must cause **marked distress in excess of what would be expected** or significant impairment in social or occupational functioning. - Given the magnitude of the stressor (losing a 20-year job), the patient's reaction is within the range of a normal and expected emotional response, rather than excessive or impairing functionality long-term. *Major depressive disorder* - Major depressive disorder requires a cluster of specific symptoms (e.g., anhedonia, sleep disturbance, appetite changes, low energy, feelings of worthlessness) lasting for at least **two weeks**, causing clinically significant distress or impairment. - The patient's symptoms are acute (6 hours), directly linked to an external event, and do not yet meet the duration or full criteria for a major depressive episode.
Explanation: **Major depressive disorder** * This patient's symptoms are suggestive of **body dysmorphic disorder (BDD)**, which has a high comorbidity with major depressive disorder. * **Depressive symptoms** like poor self-esteem, social isolation due to perceived flaws, and a focus on physical appearance often co-occur with BDD. *Anorexia* * **Anorexia** involves an extreme preoccupation with body weight and shape, leading to severe calorie restriction and a significantly low body weight (BMI < 17.5). * This patient has a normal BMI of 21 and her primary preoccupation is with perceived skin flaws rather than weight. *Malingering* * **Malingering** is the intentional production of false or grossly exaggerated physical or psychological symptoms, motivated by external incentives such as avoiding work or obtaining financial compensation. * The patient genuinely believes in her severe skin problems and is seeking treatment for them, not external gain. *Munchausen's syndrome* * **Munchausen's syndrome** (Factitious Disorder Imposed on Self) involves intentionally feigning or inducing illness to assume the sick role, without obvious external incentives. * While the patient's perception of her skin problems is distorted, she is not intentionally creating symptoms or fabricating illness for attention. *Trichotillomania* * **Trichotillomania** is an impulse control disorder characterized by recurrent, irresistible urges to pull out one's own hair. * This patient's primary complaint is severe acne and "spots" on her face, with no mention of hair pulling.
Explanation: ***Previous attempt*** - A **prior suicide attempt** is the strongest single predictor of completed suicide, increasing the risk 5-6 fold. - This patient has a history of an **overdose attempt**, indicating a higher baseline risk for future attempts. *Female sex* - While women are more likely to attempt suicide, **men are more likely to complete suicide** due to using more lethal means. - Therefore, female sex alone is not the most significant risk factor for completed suicide. *Elderly age* - The risk of suicide generally **increases with age**, particularly in elderly men; however, a prior attempt is a stronger predictor across all age groups. - While being **elderly** is a risk factor, it is less significant than a previous attempt. *Firearm possession* - The presence of a **firearm in the home increases the risk of suicide completion**, as it provides a highly lethal means. - However, for this patient, the **prior attempt** is still considered a more significant and direct risk factor for completed suicide. *No spouse* - **Social isolation** and lack of a marital partner are risk factors for suicide, as they can contribute to feelings of loneliness and lack of support. - While relevant, it is generally considered less impactful than a **previous suicide attempt** in predicting future completion.
Explanation: ***Bupropion*** - Bupropion is an antidepressant that works as a **norepinephrine-dopamine reuptake inhibitor**. It is particularly effective for patients with **depressed mood, fatigue, and difficulty concentrating**, as seen in this patient. - It is also beneficial for **nicotine cessation**, which aligns well with the patient's history of heavy smoking and failed attempts to quit. *Amitriptyline* - Amitriptyline is a **tricyclic antidepressant (TCA)** that can be sedating and has significant anticholinergic side effects, which might worsen the patient's fatigue and concentration difficulties. - TCAs are generally **not first-line** due to their side effect profile and risk in overdose compared to newer antidepressants. *Lithium carbonate* - Lithium is primarily used as a **mood stabilizer** for **bipolar disorder** and is not a first-line treatment for major depressive disorder without manic or hypomanic symptoms. - This patient's symptoms are indicative of depression, not bipolar illness. *Fluoxetine* - Fluoxetine is a **selective serotonin reuptake inhibitor (SSRI)**, a common first-line treatment for depression, but it might not be the most appropriate choice given this patient's specific presentation. - SSRIs can sometimes cause **fatigue or sexual dysfunction**, and they don't offer the added benefit for smoking cessation that bupropion does. *Valproic acid* - Valproic acid is an **anticonvulsant** primarily used as a **mood stabilizer** for bipolar disorder or for seizure control, not as a primary antidepressant in unipolar depression. - There is no indication in the patient's history or presentation to suggest bipolar disorder or a seizure disorder.
Explanation: ***Decreased norepinephrine, decreased serotonin, decreased dopamine*** - The patient's symptoms of **sadness**, loss of interest (**anhedonia**), **insomnia**, **difficulty concentrating**, and **weight loss** are classic for **major depressive disorder**. - **Depression** is strongly associated with deficiencies in **monoamine neurotransmitters**: **norepinephrine**, **serotonin**, and **dopamine**. *Decreased acetylcholine, normal serotonin, normal dopamine* - While **acetylcholine** is involved in mood regulation, its isolated decrease with normal serotonin and dopamine levels is not characteristic of generalized depression. - More prominent roles for **acetylcholine dysfunction** are seen in conditions like **Alzheimer's disease** or **myasthenia gravis**. *Decreased GABA, decreased acetylcholine, increased dopamine* - **Decreased GABA** is often associated with **anxiety disorders** and seizures, not the primary presentation of depression here. - **Increased dopamine** is more characteristic of conditions like **schizophrenia** or **mania**, which contrasts with the patient's depressive symptoms. *Increased norepinephrine, decreased serotonin, decreased GABA* - **Increased norepinephrine** is typically associated with **anxiety**, **stress**, or sometimes **mania**, which is inconsistent with this patient's depressive state. - While **decreased serotonin** is correct for depression, the combination with increased norepinephrine and decreased GABA does not fit the typical neurotransmitter profile. *Increased acetylcholine, increased serotonin, decreased dopamine* - **Increased acetylcholine** is generally not associated with the full spectrum of depressive symptoms described. - **Increased serotonin** is often the goal of antidepressant treatments (SSRIs), making an endogenous increase unlikely to cause depression.
Explanation: ***Venlafaxine*** - This patient presents with symptoms highly suggestive of **major depressive disorder**, including **anhedonia**, significant **weight loss**, **early morning awakening**, and **feelings of guilt**. His co-occurring **fibromyalgia** makes a **serotonin-norepinephrine reuptake inhibitor (SNRI)** like venlafaxine an excellent choice. - SNRIs are effective for both depression and chronic pain conditions such as fibromyalgia, as they modulate both **serotonin** and **norepinephrine** pathways, which are implicated in both mood and pain perception. *Amitriptyline* - **Amitriptyline** is a **tricyclic antidepressant (TCA)** that can be used for both depression and chronic pain, including fibromyalgia. - However, TCAs generally have a less favorable side effect profile (e.g., **anticholinergic effects**, **cardiac toxicity in overdose**) compared to SNRIs and SSRIs, making them less of a first-line choice unless other options fail or specific indications are present. *Phenelzine* - **Phenelzine** is a **monoamine oxidase inhibitor (MAOI)**, typically reserved for **atypical depression** or treatment-resistant depression due to its significant **food and drug interactions** (e.g., **hypertensive crisis** with tyramine-rich foods or sympathomimetics). - Given this is likely a first-line treatment scenario, an MAOI would not be the most appropriate initial choice. *Electroconvulsive therapy* - **Electroconvulsive therapy (ECT)** is a highly effective treatment for severe depression, especially with **psychotic features**, **catatonia**, or **severe suicidality**, or in cases of **treatment resistance** where other modalities have failed. - While the patient has significant symptoms of depression, there is no indication of immediate life-threatening severity (e.g., active suicidal intent with a plan) or treatment resistance to warrant ECT as a first-line option. *Fluoxetine* - **Fluoxetine** is a **selective serotonin reuptake inhibitor (SSRI)** and a common first-line treatment for major depressive disorder. - While it would be effective for the patient's depression, it does not offer the additional specific benefit for **fibromyalgia pain** that an SNRI like venlafaxine provides through dual serotonin and norepinephrine reuptake inhibition.
Explanation: ***Lack of concentration*** - The diagnostic criteria for a **major depressive episode** (DSM-5) require at least **5 out of 9 cardinal symptoms** present for at least 2 weeks, with at least one being either **depressed mood** or **anhedonia**. - This patient currently has **4 symptoms**: (1) depressed mood, (2) anhedonia (loss of interest in dancing/music), (3) appetite disturbance (loss of appetite), and (4) sleep disturbance (insomnia). - To meet diagnostic criteria, she needs **one more symptom** from the remaining options: fatigue, feelings of worthlessness/guilt, **diminished ability to concentrate or indecisiveness**, psychomotor changes, or suicidal ideation. - **Lack of concentration** is one of the DSM-5 diagnostic criteria and would bring her total to 5 symptoms, confirming the diagnosis. *Intense fear of losing control* - This symptom is characteristic of **panic disorder** or anxiety disorders, where individuals experience sudden, intense episodes of fear with accompanying physical and cognitive symptoms. - While anxiety can co-occur with depression, intense fear of losing control is **not a DSM-5 diagnostic criterion** for major depressive episode. *Weight loss* - The patient already has **loss of appetite**, which satisfies the weight/appetite criterion for major depressive episode. - **Weight loss and appetite changes are part of the same diagnostic criterion**, not separate ones. Therefore, weight loss would not add an additional criterion to reach the required 5 symptoms. - While clinically significant weight loss can occur in depression, it would not provide the "additional" criterion needed in this case. *Anterograde amnesia* - **Anterograde amnesia** (inability to form new memories) is associated with neurological conditions such as **hippocampal damage**, **Korsakoff syndrome**, or **traumatic brain injury**. - It is **not a DSM-5 diagnostic criterion** for major depressive episode, though some cognitive impairment (concentration difficulties) may occur. *Nightmares* - The patient already has **insomnia** (sleep disturbance), which is one of the DSM-5 diagnostic criteria. - While nightmares may occur in depression, they are not a separate diagnostic criterion and would not add to the symptom count since sleep disturbance is already present.
Explanation: ***Cognitive-behavioral therapy*** - The patient exhibits features of **body dysmorphic disorder (BDD)** including preoccupation with minor perceived flaws, repetitive behaviors (skin picking, mirror checking), and significant functional impairment (quitting activities, missing school). - She also shows **depressive symptoms** (sad affect, describes herself as "ugly"). - **Cognitive-behavioral therapy (CBT)** with exposure and response prevention is the **first-line psychotherapy** for BDD and is effective for comorbid depression. - CBT addresses maladaptive thoughts about appearance and reduces compulsive behaviors (skin picking, mirror checking). - Note: SSRIs are often used in conjunction with CBT for moderate-to-severe BDD, but among the given options, CBT is the most appropriate **next step after establishing therapeutic alliance**. *Reassure the patient that the skin findings are not severe* - Simple reassurance is **insufficient** and may be perceived as dismissive. - The patient's distress is **disproportionate to actual findings** (only "a few small papules") due to distorted self-perception characteristic of BDD. - This approach does not address the underlying **psychiatric disorder** requiring specific treatment. *Nutritional rehabilitation* - While the patient lost 5.2 kg, her **BMI remains normal** at 21.4 kg/m² (normal range: 18.5-24.9). - No evidence of malnutrition or eating disorder requiring formal nutritional rehabilitation. - Weight loss was secondary to dietary experimentation for acne, not an eating disorder. *Suggest hospitalization* - Psychiatric hospitalization is reserved for **acute safety concerns** such as imminent suicidal/homicidal risk or severe functional impairment preventing self-care. - This patient has **no suicidal ideation** on mental status examination. - While distressed with functional impairment, she does not meet criteria for inpatient hospitalization; outpatient therapy is appropriate. *Dialectical behavioral therapy* - **DBT** is specifically designed for **borderline personality disorder** with severe emotional dysregulation, chronic suicidality, and recurrent self-harm. - While the patient has skin-picking behavior, this is compulsive (part of BDD) rather than self-harm for emotional regulation. - **CBT is more appropriate** than DBT for BDD and has stronger evidence base for this condition.
Explanation: ***Depression*** - The patient exhibits classic signs of depression, including a **recent decline in mood** following her husband's death, anhedonia (sensation of heavy limbs making it difficult to do anything), and **memory difficulties** that appear to be a recent change from her previous baseline. - **Pseudodementia**, or cognitive impairment due to depression, often presents with memory complaints that resolve with treatment of the underlying mood disorder. *Vascular dementia* - This typically presents with a **step-wise decline** in cognitive function, often associated with a history of stroke or cardiovascular risk factors, which are not mentioned here. - Memory impairment in vascular dementia is often characterized by **executive dysfunction** and difficulty with information processing rather than primary memory recall alone. *Alzheimer dementia* - Characteristically involves a more **gradual and progressive decline** in memory, especially with new learning and recall, over a longer period. - While memory loss is a feature, the constellation of recent onset, mood disturbance, and lack of other neurological deficits points away from Alzheimer's as the initial diagnosis. *Hypothyroidism* - Can cause cognitive slowing and memory problems, but it typically presents with other systemic symptoms like **fatigue, weight gain, constipation, and cold intolerance**, which are not present in this patient. - The patient's vital signs are normal, and there's no mention of thyroid-related physical exam findings. *Normal aging* - While some mild memory lapses are normal with aging, the patient's complaints go beyond minor issues; she is having trouble with bills and locking doors, which indicates a **significant functional impact**. - The rapid onset of symptoms and current functional impairment suggest something beyond typical age-related cognitive changes.
Explanation: ***Selective serotonin reuptake inhibitor; anorgasmia, insomnia*** - The patient presents with classic symptoms of **major depressive disorder**, including persistent sadness, worthlessness, anxiety, and anhedonia, without any history of manic or hypomanic episodes. **SSRIs** are considered first-line pharmacotherapy for this condition. - Common side effects of SSRIs include **sexual dysfunction** (e.g., anorgasmia, decreased libido) and **insomnia** or agitation, especially during the initial weeks of treatment. *Selective serotonin reuptake inhibitor; hypomania, suicidal thoughts* - While SSRIs are the correct drug class, **hypomania** is not a frequent side effect in patients without bipolar disorder. For patients with bipolar disorder, antidepressant monotherapy can induce hypomania or mania, but this patient denies such episodes. - **Suicidal thoughts** can occur, particularly in young adults, during the initial phase of antidepressant treatment, but it is less common to frame it as a *frequently encountered side effect* in the general population compared to sexual dysfunction or sleep disturbances. *Tricyclic antidepressants; hypomania, suicidal thoughts* - **Tricyclic antidepressants (TCAs)** are generally not first-line due to their less favorable side effect profile compared to SSRIs, including significant anticholinergic effects and cardiovascular risks. - As with SSRIs, **hypomania** is not a typical frequent side effect in unipolar depression, and while **suicidal thoughts** are a concern with antidepressants, TCAs carry a higher risk of lethality in overdose, making them less preferred initially. *Monoamine oxidase inhibitors; Orthostatic hypotension, weight gain* - **Monoamine oxidase inhibitors (MAOIs)** are effective but are typically reserved for **refractory depression** due to their significant drug and food interactions (e.g., tyramine-induced hypertensive crisis). - While **orthostatic hypotension** and **weight gain** are known side effects of MAOIs, this class is not considered a first-line treatment for major depressive disorder. *Tricyclic antidepressants; Orthostatic hypotension, anticholinergic effects* - **TCAs** are indeed associated with side effects such as **orthostatic hypotension** and prominent **anticholinergic effects** (e.g., dry mouth, constipation, blurred vision, urinary retention). - However, because of these more burdensome side effects and higher toxicity in overdose, TCAs are not generally considered the first-line medication choice, especially when SSRIs are available and safer.
Explanation: ***Assess for suicidal ideation*** - The patient exhibits several **risk factors for depression**, including **insomnia**, **early morning awakening**, **anorexia**, **weight loss**, and significant **anhedonia** (lack of enjoyment in activities). - Given her age, recent loss of her husband, social withdrawal, feelings of guilt, and significant emotional distress, it is crucial to first assess for **suicidal ideation** before initiating other treatments. - **Elderly patients with depression have elevated suicide risk**, especially with recent bereavement and social isolation. Safety assessment is the **mandatory first step** in managing any patient with major depressive symptoms. *Begin mirtazapine therapy* - While **mirtazapine** is an effective antidepressant that could address several of her symptoms (insomnia, poor appetite, depression), it should only be considered after a **thorough safety assessment**, particularly for suicide risk. - Starting medication without assessing for immediate danger may overlook critical safety concerns. *Begin cognitive-behavioral therapy* - **Cognitive-behavioral therapy (CBT)** is an effective treatment for depression and could be beneficial for this patient. - However, similar to medication, it is a subsequent treatment step. The immediate priority is to rule out **suicidal intent** given the severity of her depressive symptoms. *Notify adult protective services* - There is no direct evidence of **abuse or neglect** in the provided information that would warrant involving adult protective services. - Her feelings of guilt and worry about burdening her family, while contributing to her depression, do not indicate that her son or daughter-in-law are harming her. *Recommend relocation to a nursing home* - While the patient is elderly and potentially depressed, there is no medical or social necessity presented that indicates she requires or would benefit from a **nursing home** at this stage. - This step would be premature and does not address the immediate mental health concerns or potential safety issues.
Explanation: ***Methylphenidate*** - This patient presents with **severe depression** at the end of life with a very limited prognosis (1-2 weeks), making quick symptom relief paramount. **Psychostimulants** like methylphenidate can offer a rapid antidepressant effect (within days) and improve energy and appetite. - Given her **advanced cancer**, **poor prognosis**, and **suicidal ideation**, a fast-acting treatment that improves quality of life quickly is crucial. *Electroconvulsive therapy* - While highly effective for severe depression, **ECT** requires multiple sessions and is a more invasive treatment not typically chosen for immediate symptom relief in a patient with a life expectancy of 1-2 weeks. - The patient's **metastatic cancer** and overall frail condition would make the associated risks (e.g., anesthesia) disproportionate to the limited time frame for benefit. *Megestrol* - **Megestrol acetate** is a progestin sometimes used as an appetite stimulant in patients with cachexia, particularly in cancer or AIDS. - It would not address the patient's **depressive symptoms** or **suicidal ideation**, which are the primary concerns requiring urgent intervention. *Fluoxetine* - **Fluoxetine**, a selective serotonin reuptake inhibitor (SSRI), is a common antidepressant but typically takes **4-6 weeks** to achieve its full therapeutic effect. - Given the patient's life expectancy of 1-2 weeks and her severe suicidal ideation, a delayed-onset medication like fluoxetine would not be appropriate for immediate symptom management. *Bupropion* - **Bupropion** is an antidepressant that also takes several weeks to exert its full effect. - Like other typical antidepressants, its **delayed onset of action** makes it unsuitable for a patient with such a limited prognosis needing rapid symptom relief for severe depression and suicidality.
Explanation: ***Decreased REM sleep latency*** - Patients with major depression exhibit characteristic alterations in sleep architecture, most notably a **decreased REM latency** (shortened time from sleep onset to the first REM period). - Normal REM latency is typically 90 minutes, but in depression it may be reduced to **45-60 minutes or less**. - This is one of the most **consistent and well-established polysomnographic findings** in major depressive disorder. - Other REM sleep changes include **increased REM density** (more frequent rapid eye movements) and a shift of REM sleep to the first half of the night. *Increased REM sleep latency* - This is the **opposite** of what occurs in depression. - **Decreased REM sleep latency** (shorter time to reach REM sleep) is the hallmark finding, not increased latency. - Increased REM latency might be seen in other conditions or with certain medications, but not in untreated major depression. *Associated with a seasonal pattern* - While the patient had episodes in summer and winter, the question asks specifically about **polysomnography findings**, not clinical subtypes or patterns. - Seasonal pattern is a **clinical specifier** for major depressive disorder (as in seasonal affective disorder), not a polysomnographic finding. - The seasonal pattern itself is a diagnostic feature, not something detected on sleep studies. *Increased slow wave sleep* - Depression is associated with **decreased slow-wave sleep (SWS)**, not increased. - SWS (stage N3, deep sleep) is typically **reduced** in patients with major depression. - This decrease in restorative deep sleep contributes to the poor sleep quality, daytime fatigue, and cognitive difficulties in depressed patients. *Late morning awakenings* - Major depression classically presents with **early morning awakening** (terminal insomnia), not late morning awakening. - Patients typically wake 2-3 hours earlier than desired and cannot return to sleep. - Late morning awakenings or hypersomnia may occur in **atypical depression**, but early morning awakening is the more typical pattern in melancholic depression.
Explanation: ***Persistent depressive disorder*** - The patient exhibits chronic symptoms of depression (poor appetite, poor self-esteem, difficulty with concentration, trouble with sleep, hopelessness) lasting for at least **2 years**, with symptom-free periods lasting no more than **2 months**. - Her long-standing symptoms (3 years) and the intermittent improvement, but never full resolution for extended periods, are characteristic of **persistent depressive disorder** (formerly dysthymia). *Major depressive disorder* - While the patient has many symptoms of depression, **major depressive disorder** is characterized by distinct episodes of at least 2 weeks, with significant functional impairment. The chronic, fluctuating course over 3 years is less typical. - The presence of depressive symptoms for 3 years, with only brief periods of improvement, points away from episodic major depressive disorder alone and more towards a chronic form. *Cyclothymia* - **Cyclothymia** involves numerous periods of hypomanic symptoms and numerous periods of depressive symptoms for at least 2 years, with periods of stability lasting no more than 2 months. The patient describes only depressive symptoms, not hypomanic episodes. - There is no mention of elevated mood, increased energy, or decreased need for sleep, which are characteristic of **hypomanic episodes** in cyclothymia. *Seasonal affective disorder* - **Seasonal affective disorder** is a type of depressive disorder that occurs during a specific season (most commonly winter) and resolves during other seasons; the patient's symptoms are year-round and chronic. - The patient's symptoms are not described as tied to a particular season, making this diagnosis less likely. *Disruptive mood dysregulation disorder* - Predominantly diagnosed in **children and adolescents**, this disorder is characterized by severe recurrent temper outbursts and persistently irritable or angry mood between outbursts. - The patient's age (24 years old) and the absence of temper outbursts make this diagnosis inappropriate.
Explanation: ***Attempted drug overdose*** - A **prior suicide attempt** is the single strongest predictor of future suicide completions. This patient's recent intentional overdose significantly elevates his risk. - The fact that the attempt involved a **lethal method** (opioid overdose) indicates high suicidal intent and lethality, further increasing the risk. *Male sex* - While men have a **higher rate of completed suicide** than women, male sex alone is not the strongest individual risk factor compared to a prior attempt. - This is a demographic risk factor that contributes to overall risk but does not carry the same weight as a direct behavioral indicator of suicidality. *Lack of social support* - **Social isolation** and lack of support are significant risk factors for suicide. The patient's divorce and living alone contribute to his vulnerability. - However, while important, research consistently shows that a **previous suicide attempt** is a more potent predictor of future suicide than social isolation. *Use of medical marijuana* - While **substance use disorders** (including marijuana use, especially if used to self-medicate) can increase suicide risk by impairing judgment and increasing impulsivity, it is not the strongest factor here. - There is no direct evidence presented that this patient's medical marijuana use directly triggered his current suicidal intent, unlike his documented overdose attempt. *Family history of completed suicide* - A **family history of suicide** (specifically, his mother's suicide) is a recognized risk factor, indicating genetic predisposition, environmental factors, or a learned coping mechanism. - However, a personal history of a **serious suicide attempt** carries significantly more weight in predicting future suicide completions than a family history alone.
Explanation: ***The patient has double depression.*** - The patient describes **chronic low-grade depressive symptoms** ("felt sad for as long as he can remember," "life is cursed," "difficulty making decisions," "hopeless") consistent with **persistent depressive disorder (dysthymia)**, which requires at least 2 years of symptoms. - The recent worsening of symptoms over the past two weeks, including "worsening suicidal ideations, guilt from past problems, decreased energy, and poor concentration," indicates an additional **major depressive episode (MDE) superimposed on dysthymia**, a condition known as **double depression**. - This patient currently meets criteria for both conditions simultaneously, not just at risk for developing them. *The patient may have symptoms of mania or psychosis.* - There are no symptoms mentioned that suggest **mania**, such as elevated mood, increased energy, decreased need for sleep, grandiosity, or racing thoughts. - While suicidal ideation is present, there is no evidence of **psychotic features** like hallucinations or delusions. *The patient is likely to show anhedonia.* - **Anhedonia** (inability to feel pleasure) is a common symptom of depression and may well be present in this patient. - However, the patient's presentation specifically highlights the pattern of **chronic dysthymia with a superimposed major depressive episode**, making **double depression** a more precise, comprehensive, and diagnostically specific description of his current condition. - While anhedonia might be present, it is a symptom rather than a diagnostic formulation. *The patient likely has paranoid personality disorder.* - **Paranoid personality disorder** is characterized by pervasive distrust and suspicion of others, interpreting their motives as malevolent, without sufficient basis. - The patient's feelings of being "cursed" and that "something terrible can happen" reflect **depressive pessimism and negative cognitive distortions**, not paranoid ideation about others' intentions. - This is consistent with the hopelessness seen in depression. *The patient should be started on an SSRI.* - While an **SSRI (selective serotonin reuptake inhibitor)** combined with psychotherapy would likely be appropriate treatment for double depression, making a specific treatment recommendation is premature without comprehensive clinical assessment. - The question asks for the **best statement describing the patient's condition** (diagnosis), not for treatment recommendations.
Explanation: ***Inhibit the uptake of serotonin and norepinephrine at the presynaptic cleft*** - The patient presents with symptoms characteristic of **atypical depression**, including increased sleep (**hypersomnia**), increased appetite leading to weight gain, **leaden paralysis** (heavy feelings in the limbs), and **mood reactivity** (enjoying social events/playing with children). - For initial treatment of atypical depression, **SSRIs** (e.g., fluoxetine, sertraline) and **SNRIs** (e.g., venlafaxine, duloxetine) are considered **first-line therapies** due to their favorable safety profile and efficacy. - **SNRIs** address both serotonin and norepinephrine imbalances and are effective for atypical depression, particularly when there is significant fatigue or pain. *Activates the γ-aminobutyric acid receptors* - This mechanism describes **benzodiazepines** or other GABAergic drugs, which are typically used for anxiety, insomnia, or acute agitation. - While they can provide symptomatic relief for anxiety associated with depression, they do not target the core depressive symptoms, lack antidepressant efficacy, and carry risk of dependence. *Works as an antagonist at the dopamine and serotonin receptors* - This mechanism describes **second-generation antipsychotics** (e.g., quetiapine, aripiprazole), which are primarily used to treat psychotic disorders or as adjuncts in severe depression with psychotic features or treatment-resistant depression. - The patient's symptoms do not suggest psychotic features, and antipsychotics are not first-line treatment for uncomplicated atypical depression. *Non-selectively inhibits monoamine oxidase A and B* - This describes **non-selective MAOIs** (e.g., phenelzine, tranylcypromine), which are considered the **most effective** antidepressants for atypical depression based on clinical trials. - However, MAOIs are typically reserved for **treatment-resistant depression** due to their significant side effect profile, dietary restrictions (tyramine-free diet to prevent **hypertensive crisis**), and drug interaction risks. - Given this is an initial presentation without treatment failure, MAOIs would not be the first-line choice despite their superior efficacy. *Stimulates the release of norepinephrine and dopamine in the presynaptic cleft* - This mechanism could describe **amphetamines** or certain **wake-promoting agents**, which are not standard antidepressant treatments. - **Bupropion** (an antidepressant) inhibits reuptake of norepinephrine and dopamine but does not directly stimulate their release. - Stimulants are occasionally used as adjuncts for treatment-resistant depression but are not first-line monotherapy due to abuse potential and limited evidence for long-term efficacy in depression.
Explanation: ***Continue current medication*** - It takes approximately **4-6 weeks** for an antidepressant, such as fluoxetine, to reach its full therapeutic effect and for patients to experience significant symptom improvement. - Due to the **delayed onset of action**, continuing the medication for a longer period is necessary to assess its efficacy before making changes. *Increase dose of current medication* - Increasing the dose after only 2 weeks is premature as the medication has not had sufficient time to reach its **therapeutic plasma concentration** or demonstrate its full effect. - Adjusting the dose too early could also increase the risk of **side effects** without a clear benefit. *Switch to bupropion* - Switching to a different antidepressant like bupropion after just 2 weeks is also premature, as the patient has not had an adequate trial of fluoxetine. - Bupropion has a different mechanism of action and side effect profile but also requires a similar **onset period** for efficacy. *Add lithium* - Lithium is primarily used as a **mood stabilizer** in bipolar disorder or as an augmentation strategy for treatment-resistant depression. - There is no indication of bipolar disorder, and it's too early to consider her depression as **treatment-resistant** given the short duration of fluoxetine use. *Switch to paroxetine* - Switching to another **SSRI** (selective serotonin reuptake inhibitor) like paroxetine after only 2 weeks is not appropriate because the initial SSRI has not been given sufficient time to work. - The patient has not failed therapy with fluoxetine yet, and such a change would unnecessarily prolong the search for an effective treatment.
Explanation: ***Decreased REM sleep latency*** - This patient's symptoms of **fatigue**, **anhedonia**, **sleep disturbance**, **blunted affect**, **slowed speech**, and **poor concentration** are highly suggestive of **major depressive disorder**. - **Depression** is associated with **decreased REM sleep latency** (shorter time to enter REM sleep) and **increased REM density** (more rapid eye movements during REM). *Increased periodic sharp-wave discharge* - **Periodic sharp-wave discharges** on EEG are characteristic of **Creutzfeldt-Jakob disease**, which is a **neurodegenerative prion disease**, not depression. - The patient's presentation does not align with the neurological signs typical of CJD. *Increased slow-wave sleep-cycle duration* - **Slow-wave sleep (SWS)**, or deep sleep, is typically **decreased** in patients with depression. - An increase in SWS duration would be an unusual finding in the context of major depressive disorder. *Decreased REM sleep duration* - While sleep architecture is altered in depression, total **REM sleep duration** is often **increased**, or at least not significantly decreased, in proportion to other sleep stages. - The more characteristic finding is a shorter time to reach REM sleep, not necessarily a reduction in its total duration. *Increased spike-and-wave discharge* - **Spike-and-wave discharges** are characteristic patterns seen on EEG in patients with **epilepsy**, particularly **absence seizures**. - There is no clinical or historical information to suggest an epileptic disorder in this patient.
Explanation: ***Instruct parents to remove guns from the house*** - The patient has **suicidal ideation** and access to a firearm, which is a significant risk factor for suicide attempts. Removing access to lethal means is a crucial and immediate safety measure. - While other interventions are important, securing the environment by removing firearms directly addresses an immediate and modifiable **suicide risk factor**, especially in an adolescent with depression. *Hospitalization* - Although the patient expresses suicidal thoughts, he states he has **no specific plan**, which suggests he may not require immediate inpatient psychiatric hospitalization. - Hospitalization is typically reserved for individuals with a **specific suicide plan**, intent, and significant risk that cannot be managed in an outpatient setting. *Recommend alcohol cessation* - While **alcohol use** is a concern and can exacerbate depression or suicidal ideation, addressing this is not the most immediate next step in managing acute suicide risk. - Alcohol cessation is a valuable long-term goal but does not directly mitigate the immediate danger posed by access to lethal means. *Recommend family therapy* - **Family therapy** could be beneficial in addressing family conflicts and improving communication, which might contribute to the patient's stress. - However, addressing family dynamics is a long-term intervention and does not take precedence over immediately securing the patient's safety concerning lethal means. *Contact child protective services* - There is no information in the vignette to suggest **child abuse or neglect** by the parents. - Financial problems and parental fighting, while disruptive, do not automatically constitute grounds for involving child protective services.
Explanation: ***Transference*** - **Transference** occurs when a patient unconsciously redirects feelings and attitudes from a past significant relationship (e.g., with a parent or ex-spouse) onto the therapist. - The patient is treating the therapist as if he were her ex-husband, reacting to the therapist with the same frustration and criticism she felt toward her ex-husband's perceived timidity and lack of assertiveness. - This emotional re-enactment of past relationship dynamics with the therapist is the hallmark of transference in psychotherapy. *Passive aggression* - **Passive aggression** involves indirect resistance to the demands of others and an avoidance of direct confrontation. - The patient's statement is a direct and confrontational expression of her feelings, not an indirect form of resistance. *Displacement* - **Displacement** is a defense mechanism where undesired feelings or impulses are directed from a threatening target to a safer, less threatening one. - While feelings are being redirected, the core issue is the patient's emotional re-enactment of past relationship dynamics with the therapist, which is more characteristic of transference than simple displacement. *Projection* - **Projection** is a defense mechanism where an individual attributes their own unacceptable thoughts, feelings, or impulses to another person. - The patient is not attributing her own unacknowledged timidity or lack of assertiveness to the therapist; rather, she is reacting to the therapist as if the therapist were her ex-husband. *Reaction formation* - **Reaction formation** is a defense mechanism in which a person represses unacceptable thoughts or feelings and outwardly expresses the opposite. - There is no indication that the patient is repressing certain feelings and acting in an opposing manner; her statement directly reflects her underlying frustration.
Explanation: ***Major depressive disorder*** - The patient presents with **recurrent depressive episodes** over a 3-year period, with the current episode lasting 4 weeks and including multiple depressive symptoms (insomnia, poor appetite, persistent sadness, difficulty concentrating). - The key feature is the **episodic pattern** with symptom-free intervals (maximum 1 month between episodes), indicating **recurrent major depressive disorder** rather than chronic continuous depression. - Each episode meets criteria for MDD: at least 2 weeks of depressive symptoms causing significant functional impairment (reprimanded at work, strained relationships). - The recurrent nature with clear remission periods between episodes distinguishes this from persistent depressive disorder. *Persistent depressive disorder* - Requires **chronic depressed mood** present for most of the day, more days than not, for **at least 2 years** in adults, with symptom-free periods lasting **no longer than 2 months**. - This patient has a **recurrent episodic pattern** with distinct phases separated by symptom-free periods (up to 1 month), not the continuous or near-continuous symptoms characteristic of persistent depressive disorder (dysthymia). - The presentation describes discrete episodes of depression with remissions between them, which is inconsistent with the persistent/chronic nature required for this diagnosis. *Persistent complex bereavement disorder* - This disorder involves **persistent yearning** for the deceased, intense sorrow, emotional pain, and preoccupation with the deceased, along with significant functional impairment, lasting for more than 12 months after the death. - While the patient's mother died 4 months ago, his depressive symptoms began **3 years ago** (predating the death), and the presentation lacks grief-specific features such as yearning for or preoccupation with the deceased. - The **3-year history of recurrent depressive phases** indicates a primary mood disorder rather than a bereavement-related condition. *Bipolar affective disorder* - Characterized by the presence of at least one **manic or hypomanic episode**, which involves abnormally and persistently elevated, expansive, or irritable mood with increased activity or energy. - The patient's presentation describes **only recurrent depressive episodes** without any mention of manic or hypomanic symptoms such as grandiosity, decreased need for sleep, pressured speech, racing thoughts, or reckless behavior. - Absence of any mood elevation episodes rules out bipolar disorder. *Adjustment disorder with depressed mood* - Involves emotional or behavioral symptoms developing within **3 months** of an identifiable stressor, with significant distress or functional impairment. - This diagnosis typically resolves within **6 months** after the stressor or its consequences have terminated. - The patient's **3-year history** of recurrent depressive episodes far exceeds this time frame and predates his mother's recent death, indicating a primary mood disorder rather than a stress-related adjustment reaction.
Explanation: ***Bupropion*** - Bupropion is a **norepinephrine-dopamine reuptake inhibitor** that is associated with a **lower incidence of sexual side effects** compared to SSRIs. - It would be an appropriate switch for a patient experiencing sexual dysfunction (delayed ejaculation, anorgasmia) secondary to fluoxetine, while still effectively treating depression. *Venlafaxine* - Venlafaxine is a **serotonin-norepinephrine reuptake inhibitor (SNRI)**, and like SSRIs, it can also cause **sexual dysfunction** due to its serotonergic activity. - Switching to venlafaxine would likely not resolve the patient's sexual side effects and might even worsen them. *Trazodone* - Trazodone is primarily used off-label for **insomnia** at low doses due to its strong **sedating effects** and antagonism of various receptors (e.g., histamine, alpha-1 adrenergic, serotonin 5-HT2A/C). - While it has a lower risk of sexual dysfunction than SSRIs, its antidepressant efficacy as monotherapy for major depression is generally considered **weaker** than other first-line options, and its sedating profile might not be ideal given the patient's existing fatigue. *Citalopram* - Citalopram is an **SSRI** and belongs to the same class as fluoxetine, sharing similar mechanisms of action and side effect profiles. - Switching to another SSRI like citalopram would likely result in persistent or similar **sexual dysfunction**, as this is a common class effect of SSRIs. *Tranylcypromine* - Tranylcypromine is a **monoamine oxidase inhibitor (MAOI)**, a class of antidepressants typically reserved for **refractory depression** due to their significant drug-drug and food-drug interactions. - While MAOIs can be effective, they are associated with a much **higher risk of adverse effects** (e.g., hypertensive crisis with tyramine-rich foods) and are generally not a first-line alternative after intolerance to an SSRI, especially when the current issue is sexual dysfunction.
Explanation: ***Initiation of mirtazapine*** - The patient exhibits classic symptoms of **major depressive disorder**, including insomnia, anxiety, anhedonia (loss of interest), irritability, and fatigue, all of which would benefit from an antidepressant. - **Mirtazapine** is particularly effective at lower doses for **insomnia** and **anxiety** due to its potent antihistaminergic properties, making it suitable given her chief complaint about sleep. *Initiation of risperidone* - **Risperidone** is an **antipsychotic** medication used for conditions like schizophrenia, bipolar disorder, or severe agitation, which is not indicated here given the absence of psychotic symptoms. - Its use in this context would expose the patient to unnecessary side effects such as **extrapyramidal symptoms**, **metabolic syndrome**, and hyperprolactinemia. *Psychotherapy only* - While psychotherapy, particularly cognitive-behavioral therapy (CBT), is an important component of depression treatment, the severity and acute nature of her symptoms, especially the significant functional impairment and insomnia, suggest that **pharmacotherapy is also warranted** for a more effective and rapid response. - Relying solely on psychotherapy might delay symptomatic relief, especially for her prominent **sleep disturbance** and **anxiety**. *Trial of bupropion* - **Bupropion** is an antidepressant that works primarily on **dopamine** and **norepinephrine** reuptake, and it tends to be **activating**, which could exacerbate the patient's existing **insomnia** and **anxiety**. - It lacks the sedative properties that would directly address her primary concern regarding difficulty sleeping. *Phototherapy* - **Phototherapy** is primarily used for **seasonal affective disorder (SAD)**, which is not suggested by the patient's presentation; her symptoms have been ongoing for 3 months and are linked to significant stressors, not seasonal changes. - While it can improve mood and sleep in SAD, it would not be the most appropriate or effective initial treatment for a non-seasonal major depressive episode with prominent insomnia and anxiety.
Explanation: ***Persistent depressive disorder*** - The patient exhibits classic symptoms of **persistent depressive disorder (dysthymia)**: chronic depressed mood for **at least two years**, accompanied by other depressive symptoms like **insomnia**, **difficulty concentrating**, and changes in appetite. - The duration of her symptoms (2-3 years) and the consistent feeling of sadness support this diagnosis, fitting the diagnostic criteria for **dysthymia**. *Bipolar disorder* - Bipolar disorder involves distinct episodes of **mania or hypomania** alternating with depressive episodes. - The patient's history does not indicate any periods of elevated mood, increased energy, or decreased need for sleep, which are characteristic of **bipolar disorder**. *Schizoaffective disorder* - Schizoaffective disorder is characterized by a combination of **mood symptoms** (like depression or mania) and **psychotic symptoms** (like delusions or hallucinations) occurring simultaneously or in distinct episodes. - This patient presents with no evidence of **psychotic symptoms** such as hallucinations or delusions. *Cyclothymia* - Cyclothymia is a milder, chronic form of **bipolar disorder** involving numerous periods of **hypomanic symptoms** and numerous periods of **depressive symptoms** for at least two years. - The patient's presentation lacks any history of **hypomanic episodes**, making cyclothymia an unlikely diagnosis. *Major depressive disorder* - While the patient is experiencing a **major depressive episode** currently (as suggested by increased severity in the last month and complete loss of appetite), the underlying chronic nature of her symptoms (2-3 years) and the fact that she has not been symptom-free for more than two months indicate **persistent depressive disorder**. - A diagnosis of **major depressive disorder** would typically be given if the symptoms were acute (less than 2 years) and severe, without the chronic, pervasive depressive state described.
Explanation: ***Major depressive disorder*** - The patient exhibits classic symptoms of **major depressive disorder**, including **extreme irritability**, fatigue, loss of appetite, anhedonia (quitting soccer), **hypersomnia**, academic decline, and social withdrawal. - These symptoms have been present for **3 weeks** and represent a significant change from his baseline functioning. - The severity and duration of symptoms meet **DSM-5 criteria** for a major depressive episode. *Attention deficit hyperactivity disorder* - While he shows *distractibility* and *difficulty focusing*, the **sudden onset** of multiple depressive symptoms and a clear change from his previous functioning make ADHD less likely. - ADHD is characterized by a pervasive pattern of **inattention** and/or **hyperactivity-impulsivity** typically present from childhood, not a recent decline with mood and neurovegetative symptoms. *Persistent depressive disorder* - Persistent depressive disorder (dysthymia) requires symptoms that persist for **at least 2 years** (1 year in children/adolescents) and are generally milder. - This patient's symptoms are both severe and of relatively recent onset (3 weeks), indicative of an **acute** and **major depressive episode** rather than chronic low-grade depression. *Substance abuse* - Although adolescents may use substances as coping mechanisms, there is **no evidence** of current substance use, only a history of trying alcohol twice over a year ago. - The constellation of specific depressive symptoms points away from substance abuse being the **primary diagnosis**. *Adjustment disorder with depressed mood* - Adjustment disorder requires symptoms to occur within **3 months** of an identifiable stressor and not meet full criteria for a major depressive episode. - The grandfather's death occurred **5 months ago**, which is **outside the 3-month window** for adjustment disorder. - More importantly, this patient's symptoms—including **anhedonia**, **hypersomnia**, and significant functional impairment—are severe enough to meet full criteria for a **major depressive episode**, exceeding the diagnostic threshold for adjustment disorder.
Explanation: ***Missed dose of venlafaxine*** - The patient's symptoms, including **weakness, difficulty walking, nausea, palpitations, and feeling warm**, are consistent with **venlafaxine withdrawal syndrome**. - **Venlafaxine** is an SNRI with a short half-life; abrupt cessation or missed doses can rapidly lead to withdrawal symptoms like those described. *Aspirin overdose* - **Aspirin overdose** typically presents with symptoms such as **tinnitus, hyperventilation, metabolic acidosis**, and confusion. - The patient's symptoms do not align with the classic presentation of aspirin toxicity, and laboratory results were normal. *Dehydration due to physical activity* - While gardening could lead to **dehydration**, symptoms usually include **thirst, dry mucous membranes, and orthostatic hypotension**. - This patient exhibits **hypertension** and a **rapid pulse**, which are atypical for simple dehydration. *Missed dose of lisinopril* - Missing a dose of **lisinopril** (an ACE inhibitor) could lead to an **increase in blood pressure**, but it would not typically cause acute symptoms like nausea, palpitations, or the feeling of warmth. - The patient's current blood pressure is elevated, but the constellation of other symptoms points away from this being the primary cause. *Ischemic stroke* - An **ischemic stroke** would typically present with **focal neurological deficits**, such as unilateral weakness or sensory changes. - The patient's **CT scan of the head was normal**, and her symptoms are more systemic than focal, making a stroke less likely.
Explanation: ***Initiate cognitive behavioral therapy*** - The patient exhibits features of **adjustment disorder with depressed mood**, characterized by significant distress or impairment in functioning in response to an identifiable stressor (wife leaving). - **Cognitive behavioral therapy (CBT)** is an effective first-line treatment for adjustment disorders, helping patients develop coping strategies and restructure negative thought patterns. *Prescribe a short course of alprazolam* - **Alprazolam**, a benzodiazepine, can provide temporary relief for anxiety but does not address the underlying issues of adjustment disorder and carries risks of **dependence** and withdrawal. - It would be inappropriate as a sole initial treatment and could exacerbate his **alcohol use**. *Hospitalize the patient* - The patient denies **suicidal ideation** and does not present with acute psychosis or severe impairment that would warrant **hospitalization**. - His orientation and ability to engage in conversation further suggest an outpatient approach is safe and appropriate. *Initiate disulfiram therapy* - **Disulfiram** is used for alcohol dependence to deter drinking, but the patient's current alcohol use is a recent development in response to stress, not necessarily full-blown **alcohol dependence** requiring disulfiram. - Addressing the underlying **adjustment disorder** is the priority, which may in turn reduce his alcohol consumption. *Prescribe a short course of duloxetine* - **Duloxetine** is an antidepressant that is not indicated for **adjustment disorder** as a first-line treatment, especially given the short duration and clear precipitating factor. - **Psychotherapy**, like CBT, is generally the preferred initial intervention for adjustment disorders.
Explanation: ***Malingering*** - **Malingering** involves the intentional production of false or grossly exaggerated physical or psychological symptoms, motivated by external incentives like avoiding work, obtaining drugs (e.g., narcotics for pain), or financial compensation. - The patient's history of previous ED visits for similar intractable pain, resolution with narcotics, and unremarkable CT scans, coupled with a psychiatric history consistent with characteristics of **antisocial personality disorder** (often associated with deceit and manipulation), strongly points to malingering. *Conversion disorder* - **Conversion disorder** involves neurological symptoms (e.g., paralysis, blindness, seizures) that are incompatible with recognized neurological or medical conditions, and are not intentionally feigned. - While it's a somatoform disorder, the key difference from malingering is the **lack of conscious intent** to deceive or manipulate for external gain; symptoms are not produced on purpose. *Münchhausen syndrome* - **Münchhausen syndrome** (now called Factitious Disorder Imposed on Self) is characterized by intentionally feigning or inducing illness to assume the sick role, without any obvious external rewards. - The primary motivation is the **psychological gratification** of being a patient, receiving care and attention, which differs from this case's pursuit of narcotics. *Antisocial personality disorder* - **Antisocial personality disorder** is a pervasive pattern of disregard for and violation of the rights of others, often involving deceitfulness, impulsivity, and lack of remorse, and is a *risk factor* for malingering. - While the patient exhibits characteristics of this disorder, it describes a personality type rather than directly explaining the abdominal symptoms themselves; rather, it often underlies the manipulative behaviors seen in malingering. *Opioid withdrawal* - **Opioid withdrawal** typically presents with symptoms like diarrhea, vomiting, muscle aches, and dysphoria, which are distinct from the patient's chief complaint of isolated, severe abdominal pain without nausea or vomiting. - While previous narcotic use is mentioned, the presentation doesn't fit the classic picture of withdrawal, especially with the absence of other common withdrawal symptoms and the primary focus on pain that resolves with narcotics (suggesting a desire for the drug's effects rather than alleviation of withdrawal).
Explanation: ***Ask the patient if she has an idea about how she might hurt herself*** - The patient's statement "feeling that she would be better off dead," combined with symptoms of depression (low mood, anhedonia, difficulty concentrating, low energy), indicates a **high risk of suicidality**. - Directly inquiring about **suicidal ideation and plans** is the most crucial next step to assess the immediate danger and determine the appropriate level of intervention. *Initiate pharmacotherapy with duloxetine and refer for psychotherapy* - While duloxetine is an appropriate medication for both fibromyalgia pain and depression, and psychotherapy is beneficial, these actions do not address the **immediate safety concern** regarding suicide risk. - Starting treatment without a thorough **suicide risk assessment** could be dangerous if the patient has an active plan or is imminent danger. *Ask the patient if she would voluntarily enter a psychiatric hospital* - This question is premature. Before discussing psychiatric hospitalization, it is essential to first assess the **severity and immediacy of suicidal intent** by directly asking about plans and means. - A patient may deny voluntary admission even if at high risk, requiring a different approach. *Add acetaminophen and gabapentin to the patient’s pain regimen* - This option focuses solely on pain management, which, while relevant to fibromyalgia, **fails to address the severe depressive symptoms and suicidal ideation**. - Treating pain alone without addressing the psychiatric crisis could lead to a catastrophic outcome. *Initiate pharmacotherapy with amitriptyline and refer for psychotherapy* - Amitriptyline can be used for fibromyalgia and depression, and psychotherapy is appropriate, but similar to duloxetine, this option **does not prioritize the immediate assessment of suicidality**. - A comprehensive risk assessment must precede or occur simultaneously with treatment initiation in such a high-risk scenario.
Explanation: ***Persistent depressive disorder*** - This condition is characterized by a **chronically depressed mood** that lasts for at least two years in adults, with symptoms not remitting for more than two consecutive months. - The patient's history of feeling "down" for four years, with only brief periods of relief (never exceeding one month), fits this chronic pattern and meets the diagnostic criteria for persistent depressive disorder (formerly dysthymia). - Although the patient has had worsening symptoms over the past 6 weeks, the **predominant feature** is the chronic, low-grade depression lasting 4 years, making persistent depressive disorder the most likely primary diagnosis. *Adjustment disorder with depressed mood* - An adjustment disorder typically involves emotional or behavioral symptoms in response to an **identifiable stressor**, occurring within 3 months of the stressor's onset and lasting no longer than 6 months after the stressor or its consequences have ceased. - The patient's symptoms have been ongoing for 4 years, far exceeding the typical duration for an adjustment disorder, which by definition should not persist beyond 6 months after the stressor ends. *Major depressive disorder* - Major depressive disorder involves discrete episodes of at least 2 weeks with **five or more symptoms** including depressed mood or anhedonia, plus symptoms such as changes in appetite/weight, sleep disturbance, psychomotor changes, fatigue, worthlessness/guilt, concentration difficulty, or suicidal ideation. - While the patient has some symptoms that could suggest a current major depressive episode (6 weeks of sadness, concentration difficulty, sleep problems), the question emphasizes the **chronic 4-year course** of low-grade depressive symptoms as the predominant pattern, which is more consistent with persistent depressive disorder. - Note that patients can have MDD superimposed on persistent depressive disorder ("double depression"), but the chronic pattern described here makes persistent depressive disorder the primary diagnosis. *Bipolar affective disorder* - This disorder is characterized by distinct periods of **mood episodes** that include at least one manic or hypomanic episode, in addition to depressive episodes. - The patient's presentation does not describe any manic or hypomanic symptoms (e.g., elevated mood, increased energy, decreased need for sleep, grandiosity, increased talkativeness, or risky behavior) that are characteristic of bipolar disorder. *Cyclothymic disorder* - Cyclothymic disorder involves numerous periods of **hypomanic symptoms** and numerous periods of **depressive symptoms** for at least 2 years, but these symptoms are not severe enough to meet the criteria for a hypomanic or major depressive episode. - The patient describes chronic low mood without any mention of alternating periods of elevated mood or hypomanic symptoms, which are essential for a diagnosis of cyclothymic disorder.
Explanation: ***Explain to her that she will have to be hospitalized as she is an acute threat to herself*** - This patient is actively suicidal and engaging in **self-harm (cutting)**, which represents an immediate and serious risk to her life, necessitating **involuntary hospitalization** for her safety. - In cases of acute suicidality, the ethical principle of **beneficence** (acting in the patient's best interest) and **non-maleficence** (avoiding harm) overrides confidentiality to ensure the patient's immediate safety. *Prescribe an anti-depressant medication and allow her to return home* - While an antidepressant may be part of long-term management, simply prescribing medication and sending her home is **inappropriate and dangerous** given her active suicidal ideation and self-harm. - Antidepressants can have a delayed onset of action (2-4 weeks) and, in some adolescents, may initially increase the risk of **suicidal thoughts**, making close monitoring essential. *Refer her to a psychiatrist* - A referral to a psychiatrist is crucial for comprehensive evaluation and long-term treatment, but it does **not address the immediate danger** presented by her active suicidal plans and self-harm. - An urgent psychiatric consultation or hospitalization is needed first, with a referral following stabilization. *Tell her parents about the situation and allow them to handle it as a family* - While parents must be informed, simply delegating the responsibility to them is **insufficient and potentially negligent** given the patient's acute suicidal risk. - **Medical professionals** have a duty to ensure the safety of a suicidal minor, which often requires a higher level of intervention than parental supervision alone. *Prescribe an anti-psychotic medication* - There is **no indication of psychosis** in this patient's presentation; her symptoms are consistent with severe depression and acute suicidality. - Prescribing an antipsychotic would be **inappropriate** and could cause unnecessary side effects without addressing the underlying depressive disorder or acute suicidal crisis.
Explanation: ***Retrograde amnesia*** - **Retrograde amnesia**, specifically memory loss for events occurring prior to the treatment, is a common and often transient side effect of **electroconvulsive therapy (ECT)**. - While generally temporary, it can be distressing for patients and is a significant consideration when recommending ECT, especially in patients with otherwise healthy brains. *Acute kidney injury* - **Acute kidney injury (AKI)** is not a typical direct complication of **ECT**. - While fluid and electrolyte imbalances or certain medications used during ECT (e.g., muscle relaxants) could theoretically impact renal function in predisposed individuals, it is not a primary concern in a patient with no significant history of organic illness. *Acute coronary syndrome* - **Acute coronary syndrome (ACS)** is a potential risk associated with the physiological stress of **ECT**, which can include transient **hypertension** and **tachycardia**. - However, in a 29-year-old with no significant medical history, the risk is considerably lower compared to older patients or those with pre-existing cardiovascular disease. *Anterograde amnesia* - **Anterograde amnesia**, the inability to form new memories after the treatment, is typically less common and usually milder than retrograde amnesia following **ECT**. - While some patients may experience transient difficulty recalling new information immediately post-ECT, it is usually less pronounced than the impact on remote memories. *Intracranial hemorrhage* - **Intracranial hemorrhage** is an extremely rare and severe complication of **ECT**, typically associated with pre-existing cerebral vascular abnormalities or uncontrolled hypertension during the procedure. - In a young patient with no organic illness, the risk of this complication is exceedingly low.
Explanation: ***Raphe nucleus*** - **Escitalopram** is a **selective serotonin reuptake inhibitor (SSRI)**, and the **raphe nuclei** are the primary source of serotonin production in the brain. - Serotonergic neurons originating from the raphe nuclei project widely throughout the brain, influencing mood, sleep, appetite, and cognition. *Substantia nigra* - The **substantia nigra** is primarily associated with **dopamine production**, particularly in the nigrostriatal pathway, which is crucial for motor control. - Dysfunction in this area is a hallmark of **Parkinson's disease**, not directly targeted by SSRIs for depression. *Nucleus accumbens* - The **nucleus accumbens** is a key component of the **reward pathway** and is primarily involved in dopamine and pleasure, not the primary site of serotonin production. - While dopamine dysfunction can contribute to mood disorders, SSRIs do not directly target dopamine production in this area. *Basal nucleus of Meynert* - The **basal nucleus of Meynert** is a major source of **acetylcholine** in the brain, playing a critical role in memory and learning. - Degeneration of these neurons is associated with **Alzheimer's disease**, and it is not involved in serotonin synthesis. *Locus coeruleus* - The **locus coeruleus** is the primary site of **norepinephrine production** in the brain, involved in arousal, attention, and stress responses. - While norepinephrine is implicated in mood disorders, escitalopram specifically targets **serotonin reuptake**, not norepinephrine synthesis, which occurs in the locus coeruleus.
Explanation: ***Normal cerebrum*** - The patient's presentation with acute onset confusion, fluctuating consciousness, inattention, disorganized thinking, and perceptual disturbances (misidentifying an IV line as a rope) is highly suggestive of **delirium**. - Given her history of recent medication changes (especially **clomipramine**, a tricyclic antidepressant with anticholinergic properties) and comorbidities (diabetes, hypertension, depression), she is at high risk for medication-induced or metabolic delirium. - **Delirium is a functional disturbance** without structural brain lesions; brain imaging is typically performed to rule out other causes but would show **no acute abnormalities** in uncomplicated delirium. *Mesial temporal lobe atrophy* - This finding is characteristic of **Alzheimer's disease** and would be associated with a more progressive, insidious cognitive decline rather than an acute confusional state with fluctuations. - While she has some long-standing memory issues, her acute presentation of profound disorientation and perceptual disturbances is not typical for an acute exacerbation of Alzheimer's itself, which causes mostly specific memory and cognitive decline. *Focal atrophy of the frontal and temporal cortices* - This pattern is more characteristic of **frontotemporal dementia** (FTD), which typically presents with prominent behavioral changes (disinhibition, apathy) or language difficulties. - The patient's acute fluctuating mental status is not a primary feature of FTD, which follows a more gradual, progressive course. *Caudate nucleus atrophy* - **Caudate nucleus atrophy** is a hallmark feature of **Huntington's disease**, a genetic neurodegenerative disorder characterized by involuntary movements (chorea), psychiatric symptoms, and cognitive decline. - Her symptoms of acute delirium and chronic memory loss do not align with the typical presentation of Huntington's disease. *Multiple ischemic sites and microhemorrhages* - This pattern is indicative of **vascular dementia** or multi-infarct dementia, characterized by a stepwise decline in cognitive function with focal neurological deficits. - While her comorbidities (diabetes, hypertension) increase her risk for vascular disease, her acute fluctuating delirium is more consistent with a metabolic or medication-induced cause rather than acute widespread ischemic events.
Explanation: **Having a support system** - The patient lives with his daughter, who actively cares for him, helps with medical appointments, and ensures medication adherence, indicating a strong **familial support system**. - A supportive environment and social connections are significant **protective factors** against suicide attempts. *Lack of access to sharp objects* - While removing access to lethal means is a crucial suicide prevention strategy, the patient attempted to suffocate himself, not use sharp objects. - The scenario does not explicitly state that all means of self-harm, such as suffocation methods, have been removed or restricted. *Absence of substance abuse* - The patient is noted to consume **moderate amounts of alcohol**, which can impair judgment and increase impulsivity, acting as a **risk factor** rather than a protective one. - Alcohol is a psychoactive substance associated with increased suicide risk, so this is not a protective circumstance. *Compliance with his medication* - The daughter helps the patient take his medications on time, which is beneficial for his **congestive heart failure (CHF)**, but it doesn't directly address the underlying psychological distress leading to suicidal ideation. - Though good for physical health, medication compliance alone may not be enough to prevent suicide in the presence of strong risk factors. *Absence of psychiatric comorbidities* - The patient has attempted suicide and is experiencing significant distress, suggesting underlying **psychiatric pathology** even if not formally diagnosed. - Losing his home and living in a small apartment are significant stressors that can trigger or exacerbate mental health issues.
Explanation: ***Decreased serotonin and norepinephrine*** - The patient's symptoms, including **worthlessness**, difficulty **concentrating**, loss of **interest (anhedonia)**, and **hypersomnia**, are classic for **major depressive disorder**. - **Depression** is most commonly associated with a deficiency in **monoamine neurotransmitters**, particularly **serotonin** and **norepinephrine**, which play key roles in mood, sleep, appetite, and cognition. *Increased dopamine* - **Increased dopamine** activity is more often associated with conditions like **psychosis (e.g., schizophrenia)** or the manic phases of **bipolar disorder**, which are not indicated by the patient's symptoms. - While dopamine is involved in reward and motivation, a primary increase is not the typical finding in major depression. *Increased norepinephrine* - An **increase in norepinephrine** is often seen in conditions like **anxiety disorders**, **panic attacks**, or **mania**, characterized by states of heightened arousal and vigilance. - The patient's symptoms of **lethargy**, **hypersomnia**, and **lack of energy** point away from an overall increase in norepinephrine. *Decreased acetylcholine* - **Decreased acetylcholine** is primarily linked to cognitive deficits seen in conditions like **Alzheimer's disease**, affecting memory and learning. - While depression can involve cognitive impairment, a primary deficit in acetylcholine is not the hallmark neurotransmitter change in major depressive disorder. *Decreased gamma-aminobutyric acid* - **Decreased GABA** (gamma-aminobutyric acid) is primarily associated with conditions of heightened excitability and anxiety, such as **anxiety disorders**, **insomnia**, and **seizure disorders**. - The patient's presentation of **hypersomnia** and **low energy** is inconsistent with a primary GABA deficiency.
Explanation: ***Patient is bulimic*** - The drug prescribed is **bupropion**, which is effective for both **major depressive disorder** and **smoking cessation**. - **Bupropion is absolutely contraindicated** in patients with **bulimia nervosa** or **anorexia nervosa** due to a significantly **increased risk of seizures**. - Patients with eating disorders have **electrolyte imbalances** and **metabolic disturbances** that increase seizure susceptibility, and bupropion lowers the seizure threshold. - This is an **FDA black box warning** and represents an absolute contraindication. *Patient also takes monoamine oxidase inhibitors* - While caution is required, **MAOI use is not an absolute contraindication** to bupropion. - A **washout period of 14 days** after stopping an MAOI is required before starting bupropion. - Unlike with SSRIs (where MAOI co-administration can cause serotonin syndrome), bupropion primarily affects **dopamine** and **norepinephrine** reuptake, making the interaction less severe. - This represents a **relative contraindication** requiring proper timing, not an absolute contraindication. *Patient works as a wine taster* - Working as a **wine taster** does not pose a medical **contraindication** to **bupropion**. - While excessive alcohol use should be avoided (increases seizure risk), occupational exposure to small amounts of alcohol is not a contraindication. *Patient is elderly* - **Bupropion** can be safely used in **elderly patients** with appropriate dose adjustments. - It may be preferable to other antidepressants due to favorable side-effect profile: less **sedation**, **anticholinergic effects**, and **orthostatic hypotension**. - Age alone is not a contraindication. *Patient is pregnant* - **Bupropion** is **Pregnancy Category C** (now classified as having no adequate human studies). - While generally avoided unless benefits outweigh risks, it is not an absolute contraindication. - Many pregnant women with depression and nicotine dependence may appropriately receive bupropion after careful risk-benefit assessment.
Explanation: ***Electroconvulsive therapy*** - This patient presents with **severe depression with suicidal ideation** (a failed suicide attempt), which warrants urgent intervention. **ECT** is highly effective for severe depression, especially when there is an acute suicide risk or psychotic features. - ECT has a **rapid onset of action** compared to antidepressants, which is crucial for patients at high risk of self-harm, and is considered **safe in pregnancy**. *Bupropion* - **Bupropion** is an antidepressant that primarily inhibits the reuptake of norepinephrine and dopamine. While effective for depression, it has a slower onset of action than ECT and may not be sufficient for severe, acute suicidal ideation. - It is often used for depression with atypical features or for patients who experience sexual side effects with SSRIs, but it is **contraindicated in patients with a history of seizures or eating disorders**. *Paroxetine* - **Paroxetine** is an SSRI commonly used for depression and anxiety disorders. Like other antidepressants, it has a delayed onset of action (several weeks) and may not be appropriate for the immediate management of a patient with recent, severe suicidal ideation. - One of the major concerns with paroxetine in this patient population is that it has a **higher rate of teratogenicity and neonatal complications** compared to other SSRIs, which is relevant given the patient is G1P0. *Combination of SSRI and SNRI* - Combining an **SSRI and an SNRI** (e.g., fluoxetine and venlafaxine) is a strategy sometimes used for treatment-resistant depression. However, like monotherapy with these agents, it still has a delayed onset of action. - The combination also carries a **higher risk of side effects** compared to monotherapy. *Phenelzine* - **Phenelzine** is a monoamine oxidase inhibitor (MAOI). MAOIs are effective antidepressants but are typically reserved for **treatment-resistant depression** due to their significant drug-drug and drug-food interactions (e.g., **hypertensive crisis with tyramine-rich foods or sympathomimetics**). - Given the patient's acute suicidal risk, a treatment with a more rapid and safer profile, such as ECT, would be preferred over initiating an MAOI.
Explanation: ***Adjustment disorder with depressed mood*** - This diagnosis is most likely as the patient’s symptoms (sadness, crying, loss of appetite, weight loss, difficulty getting out of bed) developed in response to an **identifiable stressor** (breakup with boyfriend) and occurred within **3 months** of its onset. - The patient's history of similar, time-limited reactions to previous relationship endings supports an adjustment disorder pattern, where symptoms are **maladaptive** but resolve once the stressor is removed or a new level of adaptation is achieved, making it distinct from major depression due to its direct and timely link to a stressor. *Bereavement* - Bereavement involves the natural and expected emotional responses to the **death of a loved one**, which is not the case here as her boyfriend left her. - While symptoms can overlap with depression, the precipitating event (death vs. breakup) distinguishes it from adjustment disorder. *Anorexia nervosa* - Anorexia nervosa is characterized by an **intense fear of gaining weight** or becoming fat, a distorted body image, and a persistent restriction of energy intake leading to a significantly low body weight. - The patient's weight loss and poor appetite are attributed to her sadness and crying spells following a breakup, not primarily driven by a desire to be thin or body image preoccupation. *Major depressive disorder* - Major depressive disorder requires symptoms to be present for **at least 2 weeks** and significantly impair functioning, but the key differentiator here is the **clear and recent precipitating stressor** (breakup) and the history of similar, time-limited responses to past relationship endings. - While the symptoms are severe, they are directly and clearly linked to the stressor, and the patient's pattern of response suggests an adjustment disorder rather than an endogenous depressive episode. *Acute stress disorder* - Acute stress disorder occurs in response to exposure to actual or threatened **death, serious injury, or sexual violence**, either directly or indirectly. - The patient's stressor (a breakup) does not meet the criteria for a traumatic event required for acute stress disorder.
Explanation: ***He has a previous attempt*** - A **history of prior suicide attempts** is the strongest predictor of future suicidal behavior. Each attempt increases the risk of subsequent attempts and eventual death by suicide. - The patient's immediate remorse and reaching out for help, while positive, do not negate the significant risk associated with the actual attempt. *His race* - While certain racial and ethnic groups may have varying suicide rates, **race alone is not the most significant independent predictor** in an individual case when compared to direct behavioral risk factors. - Socioeconomic factors and cultural influences often play a more prominent role than race itself. *He has a plan* - The patient had a plan and attempted to act on it, but the question asks for the **best predictor of *future* attempts**, not the immediate risk. - While having a plan indicates immediate risk, a **previous attempt** is a stronger longitudinal predictor of *repeated* behavior. *His lack of social support* - **Social isolation and lack of social support** are significant risk factors for suicide and can contribute to feelings of hopelessness. - However, the direct behavioral evidence of a **past attempt** is a more potent and immediate predictor of recurrence than a demographic or social factor. *His age* - **Older age can be a risk factor** for suicide, especially for white males, due to factors like chronic illness, loss of loved ones, and social isolation. - Nevertheless, a **previous suicide attempt** is a more powerful and direct indicator of future risk regardless of age.
Explanation: ***Escitalopram*** - This patient presents with **major depressive disorder**, including irritability (common presentation in adolescents), anhedonia (loss of interest in baseball), difficulty concentrating, sleep disturbance, and excessive guilt following a significant psychosocial stressor (parental divorce). - **First-line treatment for adolescent depression** is typically **psychotherapy (especially cognitive behavioral therapy)**, either alone for mild cases or combined with medication for moderate-to-severe cases. - Among the **pharmacological options provided**, **SSRIs are the preferred first-line medication class** for adolescent depression. **Escitalopram** is an appropriate choice, though **fluoxetine** has the most robust evidence in adolescents (FDA-approved for ages 8+). - Treatment typically combines pharmacotherapy with psychotherapy for optimal outcomes. *Methylphenidate* - **Methylphenidate** is a stimulant used to treat **ADHD**. - While the patient has concentration difficulties, the constellation of symptoms (irritability, anhedonia, sleep disturbance, guilt, temporal relationship to stressor) indicates **depression**, not ADHD. - Concentration problems are a common symptom of depression and typically improve with antidepressant treatment. *Buspirone* - **Buspirone** is an anxiolytic used for **generalized anxiety disorder**. - While anxiety can co-occur with depression, this patient's predominant symptoms (anhedonia, pervasive guilt, sleep disturbance, irritability) are characteristic of **major depressive disorder** rather than primary anxiety. *Quetiapine* - **Quetiapine** is an atypical antipsychotic used for **schizophrenia**, **bipolar disorder**, or as adjunctive treatment in refractory depression. - It would be **inappropriate as first-line treatment** for adolescent depression due to significant metabolic side effects (weight gain, metabolic syndrome) and lack of evidence supporting its use as monotherapy in this population. - Antipsychotics are reserved for cases with psychotic features or treatment-resistant depression. *Venlafaxine* - **Venlafaxine** is an **SNRI** (serotonin-norepinephrine reuptake inhibitor) antidepressant. - While effective for depression, **SSRIs are preferred over SNRIs as first-line pharmacotherapy in adolescents** due to better tolerability, more extensive safety data in this age group, and lower risk of adverse effects. - SNRIs are typically considered second-line options after SSRI trial failure.
Explanation: ***Generalized cerebral atrophy*** - The patient's symptoms of progressive **cognitive decline**, including difficulty with navigation and memory, are classic signs of **Alzheimer's disease**. - **Generalized cerebral atrophy**, particularly of the **hippocampus** and **temporal lobes**, is a hallmark pathological finding in Alzheimer's disease due to neuronal loss and synaptic dysfunction. *Myoclonic movements* - **Myoclonic movements** are sudden, brief, involuntary muscle jerks, most commonly associated with **Creutzfeldt-Jakob disease** or certain types of dementia with Lewy bodies, which are not suggested by the patient's presentation. - While some rare forms of early-onset Alzheimer's can have atypical features, myoclonus is not a typical or early finding in the more common late-onset presentation described. *Hallucinations* - **Hallucinations**, particularly visual hallucinations, are frequently seen in **dementia with Lewy bodies** and **Parkinson's disease dementia**, often preceding or co-occurring with cognitive decline. - While hallucinations can occur in late-stage Alzheimer's, they are not a prominent or early feature differentiating it from other dementias. *Urinary incontinence* - **Urinary incontinence** can be a symptom of various conditions, including **normal pressure hydrocephalus (NPH)**, which presents with a triad of gait instability, dementia, and urinary incontinence. - In Alzheimer's disease, incontinence typically appears in the **later stages**, after significant cognitive impairment and functional decline have occurred. *Resting tremor* - A **resting tremor** is a characteristic symptom of **Parkinson's disease** and is often seen in **Parkinson's disease dementia** or **dementia with Lewy bodies**. - The patient's neurological examination, including normal gait and muscle strength, does not suggest Parkinsonian features.
Explanation: ***Inability to participate in social events she is invited to*** - The patient's inability to participate in social events reflects **social withdrawal** and **anhedonia**, key symptoms of depression, especially with the described lack of motivation and persistent sadness. - Her prolonged sleep, increased appetite, and subjective feeling of heaviness are features of **atypical depression**, which often includes social impairment. *An increased frequency of symptoms during winter* - This characteristic is associated with **seasonal affective disorder (SAD)**, a specifier of major depressive disorder, but the patient's symptoms are described as ongoing for a month, not necessarily tied to a specific season. - While possible, the provided information does not specifically indicate a seasonal pattern, making other symptoms more directly characteristic of her current presentation. *Spells of deranged excitement* - **Deranged excitement** is a hallmark of **mania** or **hypomania**, which are features of **bipolar disorder**. - The patient's symptoms are overwhelmingly depressive (sadness, low motivation, hypersomnia, increased appetite), with no indication of elevated mood, increased energy, or racing thoughts. *Guilt related to the way she treats others* - While **guilt** can be a symptom of **major depressive disorder**, the patient's current description emphasizes **lack of motivation**, **sadness**, **hypersomnia**, and **increased appetite**, rather than specific guilt about interpersonal treatment. - The focus is more on her internal state and functional decline, rather than specific cognitive distortions about her interactions with others. *A belief that people are secretly out to sabotage her* - Such a belief indicates **paranoid delusions**, which are characteristic of **psychotic disorders** like **schizophrenia** or **major depressive disorder with psychotic features**. - The patient's presentation does not include any signs of psychosis; her symptoms align with a mood disorder without psychotic features.
Explanation: ***Penile tumescence testing*** - This test, often performed as a **nocturnal penile tumescence (NPT) test**, measures erections during sleep. The presence of normal nocturnal erections indicates a **psychogenic** cause for erectile dysfunction, as physiological mechanisms are intact. - The absence of nocturnal erections, despite adequate sleep, suggests an **organic** cause, as the body's natural erectile reflex is impaired. *Angiography* - **Angiography** is an invasive procedure used to visualize blood vessels and identify arterial blockages or abnormalities. It is typically reserved for cases where vascular disease is strongly suspected as the cause of erectile dysfunction and often considered before revascularization surgery. - While it can identify **vascular organic causes** of erectile dysfunction, it does not directly differentiate between psychogenic and organic causes universally; it focuses specifically on arterial flow. *Duplex ultrasound of the penis* - **Duplex ultrasound** evaluates blood flow within the penile arteries and veins, assessing both arterial inflow and veno-occlusive function. It aids in diagnosing **vascular abnormalities**, such as arterial insufficiency or venous leakage. - Similar to angiography, duplex ultrasound identifies specific **organic vascular pathologies** but does not definitively distinguish between psychogenic and organic causes of erectile dysfunction if vascular function is normal. *Biothesiometry* - **Biothesiometry** measures penile vibratory sensation threshold, which assesses **neurological function** of the penis. It helps detect peripheral neuropathy, a potential organic cause of erectile dysfunction, especially in diabetic patients. - While useful for uncovering **neurological organic causes**, biothesiometry does not differentiate between psychogenic and organic etiologies in cases where neurological function is normal. *Injection of prostaglandin E1* - The **injection of prostaglandin E1** (alprostadil) is a diagnostic and therapeutic tool that induces an erection by relaxing smooth muscle in the penile arteries, increasing blood flow. A strong response indicates intact vascular smooth muscle function. - A successful response to prostaglandin E1 suggests that vascular smooth muscle and neurological pathways are largely functional, which can indirectly point away from severe organic causes, but it's not a definitive differentiator between **psychogenic and organic** causes as it by-passes some physiological mechanisms.
Explanation: ***Electroconvulsive therapy*** - The patient exhibits **severe, treatment-resistant depression with active suicidal ideation and a recent attempt**, making ECT an appropriate and often life-saving intervention. - ECT is highly effective for severe depression, especially when other treatments have failed and there is an **imminent risk of suicide**. *Exposure therapy* - This therapy is primarily used for **anxiety disorders, phobias, and PTSD**, where it helps individuals confront fears. - It is not indicated for treating severe, persistent depressive episodes or acute suicidal ideation. *Cognitive behavioral therapy* - While CBT is effective for depression, this patient's **severe and refractory nature of his depression**, coupled with an active suicide attempt, indicates a need for a more rapid and intensive intervention than CBT alone can provide. - CBT by itself would generally not be sufficient for a patient with **acute suicidal risk** who has failed multiple pharmacological treatments. *Olanzapine* - Olanzapine is an **antipsychotic medication** that can be used as an adjunct in treatment-resistant depression, but it is not typically the first-line augmentation strategy after multiple antidepressant failures and is not as rapidly effective for acute suicidality as ECT. - Using an atypical antipsychotic like olanzapine alone would not address the immediate, life-threatening risk as effectively as ECT in this severe situation. *Amitriptyline* - Amitriptyline is a **tricyclic antidepressant (TCA)**, which is an older class of antidepressants. - Given the patient has failed multiple prior antidepressant trials and presents with severe, suicidal depression, starting another antidepressant, especially a TCA with its **higher side effect profile and slower onset of action**, would not be appropriate for immediate risk management.
Explanation: ***Males are more likely to die from suicide than females.*** - While females attempt suicide more often, **males complete suicide at a higher rate** due to using more lethal methods. - This patient, being an elderly male with depression and alcohol abuse, has several **risk factors for completed suicide**. *Females are more likely to self-inflict fatal injuries.* - Females are more likely to **attempt suicide**, but they generally use less lethal methods, leading to fewer completed suicides compared to males. - The **lethality of chosen methods** is a key differentiator between suicide attempts and completions between sexes. *Males are more likely to use drug overdose as a means of suicide.* - **Drug overdose** is more commonly used by females in suicide attempts, whereas males typically favor more violent and lethal means like firearms or hanging. - This difference in method choice contributes to the disparity in completed suicide rates. *Suicide risk is highest among middle-age white women.* - This statement is incorrect; **older white men have the highest suicide rate** among all demographic groups. - Risk factors like depression, social isolation, and alcohol abuse, present in the patient, are particularly common in this high-risk group. *Males attempt suicide more than females.* - **Females attempt suicide more frequently** than males. - However, males are more successful in their attempts, which is why the completed suicide rate is higher in men.
Explanation: ***Somatic symptom disorder*** - The patient's persistent, disabling urinary symptoms lack a medical explanation despite extensive workup and various treatments, fulfilling criterion A for **somatic symptom disorder**. - His excessive preoccupation with the symptom (spending time at the library researching causes, repeated evaluations, requesting a full-body CT scan) and the significant impairment in social and occupational functioning align with criterion B for the disorder. *Recurrent urinary tract infections* - The patient reports no **dysuria**, and all physical examination and laboratory studies are normal, making recurrent UTIs unlikely. - Frequent urination in UTIs is typically accompanied by other symptoms like dysuria, urgency, and sometimes hematuria. *Adjustment disorder* - Adjustment disorder is characterized by emotional or behavioral symptoms in response to an identifiable stressor, usually resolving within 6 months of stressor cessation. - While the patient has a **depressed mood**, the core issue isn't a reaction to a specific stressor but rather the chronic preoccupation with unexplained physical symptoms. *Malingering* - **Malingering** involves the intentional production of false or exaggerated physical or psychological symptoms, motivated by external incentives (e.g., financial gain, avoiding work). - There is no evidence in the vignette to suggest the patient is feigning symptoms for an external gain. *Atypical depression* - **Atypical depression** presents with mood reactivity, increased appetite/weight gain, hypersomnia, leaden paralysis, and interpersonal rejection sensitivity. - While the patient has a depressed mood and constricted affect, the primary issue is the unexplained physical symptoms and the intense preoccupation with them, rather than a classic presentation of atypical depression.
Explanation: ***Mirtazapine*** - Mirtazapine is a **noradrenergic and specific serotonergic antidepressant (NaSSA)** that blocks α2-adrenergic autoreceptors, leading to increased release of norepinephrine and serotonin. It also acts as a potent antagonist of histamine H1 receptors, which contributes to its **sedative effects** (beneficial for sleep difficulties) and its common side effect of **increased appetite and weight gain**. - Given the patient's **depressed mood, sleep disturbances, and desire to gain weight** (BMI 18.4 kg/m2 with recent weight loss), mirtazapine is an excellent choice as it addresses both her depressive symptoms and her anhedonia, while also promoting weight gain and aiding with insomnia. *Phenelzine* - Phenelzine is a **monoamine oxidase inhibitor (MAOI)**, a class of antidepressants typically reserved for **refractory depression** due to its significant drug-drug and drug-food interactions (e.g., tyramine crisis). - While it can treat depression, it is not a first-line agent, and its side effect profile does not specifically promote weight gain as a primary benefit in this context. *Lithium* - Lithium is primarily used as a **mood stabilizer** for bipolar disorder, not as an antidepressant for unipolar depression, although it can augment antidepressant treatment. - While weight gain can be a side effect of lithium, its primary indication and other side effects (e.g., nephrogenic diabetes insipidus, hypothyroidism) make it an inappropriate first-line choice for this patient's presentation. *Olanzapine* - Olanzapine is an **atypical antipsychotic** used for schizophrenia and bipolar disorder, and sometimes as an adjunct in severe depression, particularly with psychotic features. - While it can cause significant weight gain, its primary indications and potential metabolic side effects (e.g., hyperglycemia, dyslipidemia) make it an unsuitable first-line treatment for depression with simple weight loss unless psychotic features are present, which this patient does not have. *Topiramate* - Topiramate is an **anticonvulsant** used for epilepsy, migraine prevention, and sometimes off-label for weight loss. - It is known for causing **weight loss and anorexia**, making it contraindicated for a patient who desires to gain weight and has a history of anorexia nervosa.
Explanation: ***Dissociative amnesia*** - This condition is characterized by an inability to recall important **autobiographical information**, usually of a **traumatic or stressful nature**, which is inconsistent with ordinary forgetting. The patient's inability to remember a stressful past job event, confirmed by her husband, fits this description. - The absence of other memory or cognitive deficits (e.g., remembering marriage date, recent meals, normal orientation) and lack of other defining features for other dissociative or amnestic disorders makes dissociative amnesia the most likely diagnosis. *Dissociative fugue* - Dissociative fugue involves sudden, unexpected travel away from home or one’s usual daily activities, along with **amnesia for identity** or other important autobiographical information. The patient in this case denies any such travel or confusion about her identity. - While it includes amnesia, the key distinguishing feature of fugue, such as wandering or bewildered behavior, is absent in this patient. *Transient global amnesia* - This condition is characterized by a sudden onset of **anterograde amnesia** (inability to form new memories) and sometimes retrograde amnesia for recent events, typically lasting hours. It is often preceded by physical or emotional stress, but the patient usually recovers within 24 hours. - The patient's amnesia is specific to a past stressful event and not for current or recent events, and her memory loss extends beyond a few hours, which differentiates it from transient global amnesia. *Pseudodementia* - Pseudodementia is a term used to describe cognitive impairment, particularly memory loss, that is caused by **depression** and not by a neurodegenerative process. The patient's husband mentions low mood, but she denies other significant depressive symptoms like anhedonia, suicidal ideation, or vegetative symptoms. - While there is a mention of low mood, the specific and circumscribed nature of her memory loss to a particular stressful event, without other widespread cognitive deficits or a clear major depressive episode, makes this less likely. *Dissociative identity disorder* - Dissociative identity disorder (formerly multiple personality disorder) involves the presence of **two or more distinct personality states** or an experience of possession, along with recurrent gaps in the recall of everyday events, important personal information, and/or traumatic events. - This patient does not exhibit any signs of distinct personality states or possession, which is a hallmark feature of dissociative identity disorder.
Explanation: ***Involuntary hospitalization after informing the parents*** - The patient expresses a clear **intent to die** by suicide ("better off dead," "want to use his father's licensed firearm to end his misery") and has a **plan** with specific means and timing ("over the weekend when his parents are at church"). This constitutes an imminent danger to himself, warranting **involuntary hospitalization** for safety. - As a minor, his parents must be informed and involved in the decision regarding his hospitalization, which is necessary to prevent him from acting on his suicidal ideations. *Start outpatient psychotherapy* - Outpatient psychotherapy is **insufficient** given the patient's immediate and high risk of suicide. - The patient clearly states he is not in the mood to see friends and family, indicating a lack of motivation for treatment and a high risk of non-compliance with outpatient care. *Reassure the patient that he will feel better* - Reassurance alone is **inappropriate** and **ineffective** for a patient with severe depression and active suicidal ideation with a plan. - This approach fails to address the immediate safety concerns and the underlying mental health crisis. *Begin paroxetine therapy* - While an antidepressant like paroxetine may be part of eventual treatment for depression, it is **not the immediate next step** in a patient with acute suicidal intent. - Antidepressants take several weeks to become effective, and during the initial phase, there can be an increased risk of suicidality in adolescents. *Agree to his wish for no further treatment* - Agreeing to his wish would be a **gross medical and ethical negligence** given his expressed suicidal intent and plan. - A healthcare provider has a duty to protect patients from harm, especially minors who are not in a position to make sound decisions regarding their own safety due to mental illness.
Explanation: ***Transient global amnesia*** - The sudden onset of **anterograde amnesia** (inability to form new memories after the event) and **retrograde amnesia** (inability to recall events before the attack) with preserved consciousness and other neurological functions is characteristic. - This condition is typically short-lived, with full recovery of memory within **24 hours**, although patients may have a residual gap in their memory of the event itself. *Dissociative amnesia* - This involves an inability to recall important **personal information**, usually of a traumatic or stressful nature, that is inconsistent with ordinary forgetting. - It is often preceded by severe **psychological stress** and does not typically involve the repetitive questioning seen in the patient. *Migraine* - While the patient has a history of migraines, a typical migraine attack primarily involves a **headache**, often with an aura, and does not usually present with isolated acute amnesia. - **Amnestic migraine** is rare and usually associated with other migraine features, which are not described here. *Seizure* - Absence or complex partial seizures can cause periods of **altered consciousness** and unresponsiveness, but patients typically do not continuously ask the same questions or maintain full interaction as described. - Post-ictal confusion generally resolves more quickly or has different features compared to the repetitive questioning observed. *Depersonalization/derealization disorder* - This disorder is characterized by persistent or recurrent feelings of being **detached from one's mental processes or body** (depersonalization) or from one's surroundings (derealization). - It would not typically present as an acute, sudden onset of memory loss and repetitive questioning about one's location or recent events.
Explanation: ***Major depressive disorder*** - The patient presents with **multiple symptoms of depression** (fatigue, sadness, anhedonia, insomnia, appetite loss, weight loss) that meet DSM-5 criteria for a major depressive episode, including **suicidal ideation** with a specific plan. - Although triggered by bereavement, the **severity** (15-pound weight loss, complete withdrawal from activities, active suicidal ideation) and **duration** (3 months) indicate a major depressive episode rather than uncomplicated grief. - The auditory hallucination (hearing husband's voice) in the context of severe depression with multiple vegetative symptoms constitutes **MDD with psychotic features**. - DSM-5 allows diagnosis of MDD during bereavement when symptoms are severe, persistent, and include features like **psychotic symptoms** or **active suicidal ideation**. *Bipolar II disorder* - This disorder requires documented episodes of **hypomania** (elevated mood, increased energy, decreased need for sleep) in addition to depressive episodes. - While the patient experiences severe depressive symptoms, there is **no history of hypomanic episodes**, making bipolar II disorder unlikely. *Acute grief* - Acute grief is a normal response to loss and can include sadness, preoccupation with the deceased, and even brief hallucinations of hearing or seeing the deceased. - However, uncomplicated grief typically does **not** include persistent severe vegetative symptoms (15-pound weight loss, early morning awakening), complete **anhedonia** with functional impairment, or active **suicidal ideation with a plan**. - The **severity and constellation** of symptoms (particularly suicidal planning and marked functional impairment) exceed normal grief and indicate MDD. *Persistent depressive disorder* - This disorder (dysthymia) involves chronic depressed mood for **at least two years** with less severe symptoms than MDD. - This patient's symptoms have been present for only **3 months** and are **too severe** (psychotic features, active suicidal ideation, significant weight loss) for persistent depressive disorder. - The acute onset following bereavement and severity of symptoms align with MDD rather than the chronic, lower-grade depression of persistent depressive disorder. *Schizoaffective disorder* - This disorder requires **psychotic symptoms** (hallucinations or delusions) present for at least two weeks **in the absence of a major mood episode**. - In this patient, the hallucination occurs **exclusively within the context** of a severe depressive episode, which is characteristic of **MDD with psychotic features**, not schizoaffective disorder. - There is no evidence of psychotic symptoms occurring independently of mood symptoms.
Explanation: ***Bupropion*** - **Bupropion** is an antidepressant that works by inhibiting the reuptake of **norepinephrine and dopamine**, making it effective for depression with symptoms like **fatigue, low motivation, and anhedonia**. - It has a lower risk of **sexual dysfunction** compared to SSRIs/SNRIs and can aid in **smoking cessation**, which addresses two of the patient's major concerns. *Fluoxetine* - **Fluoxetine**, an **SSRI**, is a first-line treatment for depression, but it often causes or worsens **sexual dysfunction**, which is already a significant complaint for this patient. - While effective for depression, it does not offer the additional benefit of aiding in **smoking cessation** that bupropion provides. *Venlafaxine* - **Venlafaxine**, an **SNRI**, is effective for depression, but like SSRIs, it can cause or exacerbate **sexual dysfunction**, which the patient is already experiencing. - It does not have a distinct advantage for **smoking cessation** or minimizing sexual side effects in this presentation. *Mirtazapine* - **Mirtazapine** is an antidepressant that primarily works by enhancing noradrenergic and serotonergic neurotransmission; it is associated with side effects like **sedation** and **weight gain**. - While it has a lower incidence of **sexual side effects** than SSRIs/SNRIs, it does not provide the additional benefit of **smoking cessation** support, and its sedating effects might worsen her daytime tiredness. *Trazodone* - **Trazodone** is primarily used off-label for **insomnia** due to its sedating effects and is generally not a first-line agent for major depressive disorder when symptoms like fatigue and anhedonia are prominent. - While it has a low risk of sexual dysfunction, it doesn't address the patient's need for **smoking cessation** support and might worsen daytime fatigue.
Explanation: ***Maintain the current dose of citalopram for several months*** - The patient has achieved **full remission** of her depressive symptoms and is tolerating the medication well, indicating the current dose is effective. - For a first episode of major depressive disorder, continuing antidepressant treatment for **6-12 months** after achieving remission is recommended to prevent relapse. *Lower the dose of citalopram* - Lowering the dose prematurely could increase the risk of **relapse** given that the patient has only recently achieved remission and the standard duration of maintenance treatment has not been met. - While side effects can sometimes warrant dose reduction, this patient is **no longer experiencing side effects** and is tolerating the current dose well. *Discontinue the citalopram* - Discontinuing the medication at this stage would significantly increase the risk of **relapse** within a short period, as the brain has not had sufficient time to stabilize. - The recommended duration for maintenance treatment after remission of a first depressive episode is typically **6-12 months**, which this patient has not yet completed. *Discontinue the citalopram and switch to amitriptyline* - This is inappropriate because the patient is responding very well to citalopram, experiencing **full remission** and good tolerability. - Switching to another antidepressant like **amitriptyline** (a tricyclic antidepressant) would expose her to potential new side effects and risks, including a less favorable side effect profile compared to SSRIs. *Increase the dose of citalopram* - The patient has reached **full remission** of her symptoms, indicating that the current dose is therapeutic and effective. - Increasing the dose further would be unnecessary and could potentially introduce **new or worsened side effects** without providing additional clinical benefit.
Explanation: ***This patient must have anhedonia or depressed mood.*** - According to the **DSM-5 criteria** for Major Depressive Disorder, at least one of the two core symptoms must be present: **depressed mood** or **anhedonia** (loss of interest or pleasure). - The patient's presentation with "depressed mood" directly fulfills this essential diagnostic requirement. *This patient’s symptoms must have been present for at least 1 month.* - For a diagnosis of major depressive disorder, symptoms must be present for a minimum duration of **2 weeks**, not 1 month. - The vignette states "over the past several weeks," which is consistent with the 2-week minimum, but not necessarily 1 month. *This patient has preserved social and occupational functioning.* - The patient **cannot go to work**, which indicates a significant impairment in **occupational functioning**. - Major Depressive Disorder inherently involves clinically significant distress or impairment in social, occupational, or other important areas of functioning. *This patient may have pressured speech.* - **Pressured speech** is characteristic of **mania or hypomania**, not major depressive disorder. - In depression, speech is typically slowed, reduced in volume, or entirely absent in severe cases. *This patient may have a history of elated mood.* - A history of **elated mood**, particularly if involving manic or hypomanic episodes, would suggest a diagnosis of **bipolar disorder**, not major depressive disorder. - The absence of such a history is crucial for maintaining a diagnosis of major depressive disorder.
Explanation: ***Postpartum depression for mother*** - A history of **eating disorders** significantly increases the risk of **postpartum depression** and anxiety due to psychological vulnerabilities and potential nutritional deficiencies. - The stress of pregnancy, childbirth, and motherhood can trigger a relapse or worsen existing psychiatric conditions, making **postpartum depression** a common complication. *Bradycardia in newborn* - **Bradycardia** in a newborn is typically associated with conditions like fetal distress during labor, congenital heart defects, or hypoxia, not directly with a mother's past eating disorder history. - While an eating disorder can affect maternal health, it's not a primary direct cause of neonatal **bradycardia**. *Seizure for mother* - **Seizures** in pregnant women are commonly linked to severe preeclampsia/eclampsia, epilepsy, or other neurological conditions. - A past history of eating disorders does not directly predispose a mother to **seizures** during pregnancy or postpartum unless accompanied by severe electrolyte imbalances, which are usually managed. *Down syndrome in newborn* - **Down syndrome** is a genetic condition caused by an extra copy of chromosome 21 (Trisomy 21) and is primarily associated with advanced maternal age. - There is no established causal link between a maternal history of **eating disorders** and the occurrence of **Down syndrome** in the newborn. *Anemia in newborn* - **Anemia** in a newborn can result from various factors such as maternal **anemia**, blood loss during delivery, or hemolytic disease. - While maternal eating disorders can cause nutritional deficiencies, including maternal **anemia**, this does not directly result in **anemia** in the newborn unless those deficiencies are severe and uncorrected, or if other, more direct causes are present.
Explanation: ***Depressed mood and feeling of guilt*** - Patients with **panic disorder** often develop secondary **depressive symptoms** due to the chronic stress, fear of attacks, and avoidance behaviors that significantly impair their quality of life. - The recurrent, unpredictable nature of panic attacks and associated impairment in daily functioning can lead to feelings of **hopelessness, guilt**, and **anhedonia**. *Abnormally elevated mood and flight of ideas* - This constellation of symptoms is characteristic of a **manic episode** in **bipolar disorder**, which is not indicated by the patient's presentation of panic attacks. - The patient's primary concern is anxiety and fear surrounding episodes, not elevated mood or racing thoughts. *Preoccupation with an observed flaw in physical appearance* - This is a core feature of **body dysmorphic disorder**, where individuals are excessively preoccupied with perceived defects in their physical appearance. - The patient's symptoms are focused on acute physical and psychological distress (palpitations, chest pain, fear of losing control), not appearance. *Fear of spiders and heights* - These are examples of **specific phobias** (arachnophobia and acrophobia, respectively). - While panic attacks can occur in the context of specific phobias, the patient's attacks are recurrent, unexpected, and not tied to specific objects or situations like spiders or heights. *Disorganized speech and delusions* - These are prominent symptoms of **psychotic disorders** such as **schizophrenia**. - The patient's presentation involves acute anxiety symptoms and fear of losing control, without evidence of thought disorder or delusions.
Explanation: ***Suicidality*** - Trauma survivors, especially those who have experienced sexual assault, are at a significantly **higher risk for developing suicidal ideation and attempting suicide**. This risk is amplified due to the psychological distress, feelings of helplessness, guilt, and shame often associated with such traumatic events. - The emotional impact of rape can lead to severe **depression, anxiety, and post-traumatic stress disorder (PTSD)**, all of which are strong risk factors for suicidality. *Schizoaffective Disorder* - This is a chronic mental health condition characterized by a combination of **schizophrenia symptoms, such as hallucinations or delusions, and mood disorder symptoms, such as mania or depression**. - While trauma can exacerbate existing mental health conditions, there is no direct causal link between a single traumatic event like rape and the development of schizoaffective disorder. *Attention Deficit Hyperactivity Disorder* - ADHD is a **neurodevelopmental disorder** typically diagnosed in childhood, characterized by inattention, hyperactivity, and impulsivity. - It is not caused by traumatic events in adulthood; its onset is usually in early development. *Bipolar Disorder* - Bipolar disorder is a **mood disorder** characterized by significant mood swings, including episodes of mania or hypomania and depression. - While stress and trauma can sometimes trigger episodes in individuals predisposed to bipolar disorder, rape itself is not a direct cause of developing the disorder. *Schizophrenia* - Schizophrenia is a **chronic psychotic disorder** characterized by significant thought disturbances, hallucinations, delusions, and disorganized behavior. - The onset of schizophrenia is often in late adolescence or early adulthood, but it is primarily a **neurobiological disorder** and not directly caused by a single traumatic event like rape.
Explanation: ***Normal bereavement*** - The patient's symptoms (sleep disturbance, sadness, weight loss, crying spells, auditory hallucinations of a loved one) are all **common and expected responses to the death of a loved one** within a short timeframe (1 month). - Her continued social engagement and lack of suicidal ideation suggest that her grief, while intense, is within the range of **normal bereavement**, especially given the recent and traumatic loss. *Adjustment disorder with depressed mood* - This diagnosis is considered when symptoms in response to a stressor are **clinically significant** but do not meet criteria for a major depressive episode and cause significant impairment. - However, in this case, the symptoms are directly related to the death of her husband, making **bereavement a more specific and appropriate diagnosis** if the symptoms are within normal grief. *Acute stress disorder* - This disorder typically involves exposure to actual or threatened **death, serious injury, or sexual violence**, followed by intrusive symptoms, negative mood, dissociation, avoidance, and arousal symptoms, and lasts from 3 days to 1 month. - While there is a significant stressor (husband's death), her symptoms are more indicative of **grief and loss** rather than the specific dissociative, avoidance, and arousal symptom clusters required for acute stress disorder. *Major depressive disorder* - While some symptoms overlap (depressed mood, sleep disturbance, weight loss), several factors argue against MDD, such as the direct and recent link to a **major loss**, her **intact social functioning**, and the **absence of suicidal ideation** or pervasive anhedonia beyond grief. - The **auditory hallucinations of her husband's voice** are also common in normal bereavement, especially shortly after a loss, and do not necessarily indicate a psychotic disorder or MDD with psychotic features in this context. *Schizoaffective disorder* - This diagnosis requires a **period of illness during which a major mood episode is present concurrently with Criterion A of schizophrenia** (delusions, hallucinations, disorganized speech, grossly disorganized or catatonic behavior, negative symptoms) and delusions or hallucinations for 2 or more weeks in the absence of a major mood episode. - The patient's isolated auditory hallucination, occurring in the context of profound grief, does not meet the extensive criteria for schizophrenia or schizoaffective disorder, and there are **no other psychotic symptoms** or a history of such.
Explanation: ***Continue sertraline for 3 more weeks*** - Antidepressants like **sertraline** typically require **4 to 6 weeks** to reach their full therapeutic effect. - Since only three weeks have passed with minor improvements, the patient should continue the medication to allow time for the drug to work fully. *Augment with aripiprazole and continue sertraline* - **Augmentation** with an atypical antipsychotic like aripiprazole is considered if there is **no significant improvement after an adequate trial** (at least 6-8 weeks) of antidepressant monotherapy. - It is too early to consider augmentation as the patient has not completed a sufficient trial of sertraline. *Provide electroconvulsive therapy* - **Electroconvulsive therapy (ECT)** is reserved for **severe, treatment-resistant depression**, depression with psychotic features, or when rapid response is required (e.g., severe suicidality). - The patient's symptoms, while bothersome, do not meet criteria for severe, treatment-resistant depression or acute emergencies warranting ECT. *Change medication to duloxetine* - Changing antidepressants is usually considered if there is **minimal or no response** after an adequate trial of the initial medication. - Switching medications before allowing sufficient time for the current treatment to work is premature and may delay effective treatment. *Augment with phenelzine and continue sertraline* - **Phenelzine** is a **monoamine oxidase inhibitor (MAOI)**, and using it in combination with an **SSRI like sertraline** is contraindicated due to the risk of **serotonin syndrome**. - MAOIs are generally reserved for **refractory depression** due to their dietary restrictions and potential for severe drug interactions.
Explanation: ***Electroconvulsive therapy*** - This is generally reserved for **severe depression** that is unresponsive to other treatments or for depression with **psychotic features**, severe suicidality, or catatonia. - Given the patient's presentation, **ECT** would be an overly aggressive **first-line** treatment choice. *Paroxetine* - **Paroxetine** is a **SSRI** and is considered a **first-line antidepressant** for major depressive disorder. - It works by increasing serotonin levels in the brain to improve mood. *Citalopram* - **Citalopram** is an **SSRI** and is also a **first-line treatment option** for major depressive disorder, often well-tolerated. - It helps regulate mood and alleviate symptoms like those described by the patient. *Psychotherapy* - **Psychotherapy**, particularly **cognitive-behavioral therapy (CBT)** or **interpersonal therapy (IPT)**, is often a **first-line treatment**, either alone or in combination with medication, for depression. - It can help the patient address negative thought patterns and coping mechanisms. *Sertraline* - **Sertraline** is another **SSRI** commonly used as a **first-line agent** for major depressive disorder due to its efficacy and relatively favorable side-effect profile. - It helps to improve symptoms such as low mood, sleep disturbances, and decreased appetite.
Explanation: ***Continue sertraline*** - **Antidepressants**, especially SSRIs like sertraline, typically take **4-6 weeks** to reach their full therapeutic effect. The patient has only been on the medication for 2 weeks. - The patient has shown **significant improvement** in sleep and appetite, indicating the medication is starting to work. **Weight gain** often lags behind other symptomatic improvements. *Add amitriptyline to sertraline* - Adding a **tricyclic antidepressant (TCA)** like amitriptyline to an SSRI is generally reserved for **treatment-resistant depression** after an adequate trial of monotherapy or augmentation with a non-TCA agent. - This combination also increases the risk of **serotonin syndrome** due to synergistic serotonergic effects. *Replace sertraline with fluoxetine* - Switching to another SSRI after only 2 weeks is **premature**, especially when there are signs of improvement. - There is no clinical indication that sertraline is ineffective at this stage; **insufficient time** has passed to assess its full efficacy. *Add fluoxetine to sertraline* - Combining two SSRIs is generally **not recommended** as it significantly increases the risk of **serotonin syndrome** without a clear benefit over monotherapy or augmentation with a different class of medication. - This approach does not follow standard treatment guidelines for initial management of depression. *Discontinue sertraline* - Discontinuing the medication after only 2 weeks, especially when there are signs of **partial response** (improved sleep, appetite), is inappropriate. - This could lead to a **resurgence of symptoms** and an incorrect conclusion that the medication was ineffective.
Explanation: ***Fluoxetine*** - Fluoxetine, a **selective serotonin reuptake inhibitor (SSRI)**, is known to cause or worsen sexual dysfunction, which is already a concern for this patient given his history of **erectile dysfunction**. - While effective for depression, the potential to exacerbate a pre-existing condition makes it a less favorable choice in this specific clinical scenario. *Vilazodone* - Vilazodone is a **serotonin partial agonist/reuptake inhibitor (SPARI)** that generally has a **lower incidence of sexual side effects** compared to traditional SSRIs. - This characteristic makes it a potentially more suitable option for a patient with pre-existing erectile dysfunction. *Vortioxetine* - Vortioxetine is a **multimodal antidepressant** that also tends to have a **lower impact on sexual function** compared to many other antidepressants. - Its mechanism of action, involving serotonin reuptake inhibition and modulation of various serotonin receptors, contributes to its generally favorable sexual side effect profile. *Mirtazapine* - Mirtazapine is an **agonist at presynaptic alpha-2 adrenergic receptors** and also blocks 5-HT2 and 5-HT3 receptors. Unlike SSRIs, it is often associated with a **lower risk of sexual dysfunction**. - Additionally, its **sedating properties** could be beneficial for this patient who is struggling with sleep, making it a potentially good choice. *Bupropion* - Bupropion is a **norepinephrine-dopamine reuptake inhibitor (NDRI)** and is known to have a **minimal impact on sexual function**, often being chosen for patients who experience sexual side effects with other antidepressants. - It also has an **activating effect** which could help with the patient's low energy and lack of motivation.
Explanation: ***Suppression*** - The patient consciously avoids thinking about his mother's death by **deliberately redirecting his thoughts** to baseball tryouts. - He is aware of the grief but chooses to **postpone acknowledging** it openly. *Displacement* - Involves **redirecting emotions** (often anger or frustration) from the original source to a less threatening target. - The patient isn't expressing his grief towards an unrelated object or person; he's avoiding the grief itself. *Denial* - Characterized by a **refusal to accept reality** or a painful fact as if it doesn't exist. - The patient here shows awareness of his mother's death (tearing up) rather than outright denying its occurrence. *Rationalization* - Involves **creating logical-sounding excuses** or justifications for unacceptable thoughts, feelings, or behaviors. - The patient isn't making excuses; he's actively, though consciously, avoiding the painful emotional topic. *Repression* - An **unconscious mechanism** where unacceptable thoughts, feelings, or memories are blocked from conscious awareness. - Repression is an involuntary process, whereas the patient's shift to baseball is a conscious effort to avoid the topic.
Explanation: ***Depression with peripartum-onset*** - The patient exhibits classic symptoms of **major depressive disorder**, including **anhedonia** (loss of enjoyment in cooking), **fatigue**, **insomnia**, and **changes in appetite/weight**, all appearing within 3 weeks post-childbirth and persisting for 9 months. - According to **DSM-5-TR**, the **peripartum onset specifier** is applied when a major depressive episode begins during pregnancy or **within 4 weeks after delivery**. - This patient's symptoms began at 3 weeks postpartum, meeting criteria for the peripartum onset specifier, which is clinically important for risk assessment (including infanticide risk) and treatment planning. - The severity and duration of symptoms (persistent anhedonia, significant fatigue, insomnia despite adequate opportunity for sleep, appetite changes, functional impairment lasting months) clearly meet criteria for a **major depressive episode**. *Adjustment disorder* - This diagnosis involves emotional or behavioral symptoms in response to an identifiable stressor that do **not meet criteria for a major depressive episode**. - The severity, number, and duration of symptoms (anhedonia, significant fatigue, insomnia, appetite changes, functional impairment lasting 9 months) exceed what is seen in adjustment disorder and meet full criteria for **major depressive disorder**. *Major depressive disorder* - While this patient's symptoms fully meet criteria for **Major Depressive Disorder (MDD)**, the onset within 4 weeks postpartum requires the addition of the **"with peripartum onset" specifier** per DSM-5-TR. - Using the peripartum onset specifier is essential for clinical management, as it alerts clinicians to specific risks (including thoughts of harming the infant) and may influence treatment selection (e.g., considerations for breastfeeding-compatible medications). *Normal behavior* - The patient's symptoms—including **persistent sadness lasting 9 months**, **anhedonia**, **insomnia despite adequate sleep opportunity**, **significant fatigue**, **appetite loss**, and **inability to return to work**—represent severe functional impairment. - These symptoms far exceed normal postpartum adjustment or transient "baby blues" (which typically resolve within 2 weeks postpartum) and indicate a serious mood disorder requiring treatment. *Disruptive mood dysregulation disorder* - This disorder is diagnosed **only in children and adolescents aged 6-18 years** and is characterized by persistent irritability and frequent, severe temper outbursts disproportionate to the situation. - It is **not applicable to adults** and does not describe this patient's presentation of persistent depressed mood and neurovegetative symptoms.
Explanation: ***Escitalopram therapy*** - The patient presents with symptoms consistent with **major depressive disorder**: generalized fatigue, anhedonia (stopped playing drums, attending family events), poor concentration, and hypersomnia (sleeping in class) for 3 months. - An **SSRI like escitalopram** is a first-line pharmacotherapy for MDD, particularly given its good tolerability profile and effectiveness in addressing core depressive symptoms. *Diazepam therapy* - **Diazepam is a benzodiazepine**, primarily used for acute anxiety or insomnia, and can be habit-forming. - It is not indicated as a first-line treatment for major depressive disorder due to its addictive potential and lack of efficacy for core depressive symptoms. *Phenelzine therapy* - **Phenelzine is a MAOI (monoamine oxidase inhibitor)**, which are older antidepressants typically reserved for atypical depression or treatment-resistant depression due to their significant side effects and dietary restrictions. - It is not appropriate as a first-line agent, especially given safer and equally effective options like SSRIs. *Reassurance* - The patient's symptoms are significant, persistent for 3 months, and causing functional impairment (decline in grades, social withdrawal); therefore, **simple reassurance is insufficient** and would delay appropriate treatment. - These symptoms warrant a more proactive and evidence-based therapeutic approach. *Amitriptyline therapy* - **Amitriptyline is a TCA (tricyclic antidepressant)**, which are generally associated with a higher incidence of side effects, such as anticholinergic effects, sedation, and cardiac conduction abnormalities, compared to SSRIs. - While effective for depression, it is typically not a first-line treatment due to its less favorable side effect profile compared to SSRIs like escitalopram.
Explanation: ***Pseudodementia*** - The rapid onset of symptoms (within the last month), coupled with the patient's **depressed mood** (feeling 'down', low energy, flat affect, recent loss of spouse), strongly suggests **pseudodementia**, which is cognitive impairment mimicking dementia but caused by depression. - Patients with pseudodementia often highlight their **memory problems**, get defensive about cognitive failures, and show a more global cognitive decline rather than specific deficits, all of which are present in this case. *Pick’s disease* - This is a form of **frontotemporal dementia** characterized by prominent behavioral changes and language difficulties, which are not the primary features here. - Cognitive decline in Pick's disease is typically **insidious and progressive**, not acute and linked to a depressive episode. *Delirium* - Delirium is characterized by an **acute onset of fluctuating attention** and **altered consciousness**, often with disorientation and disorganized thinking. - There is no mention of fluctuating mental status or altered consciousness, and the patient's presentation points more towards a mood disorder impacting cognition over a few weeks, rather than hours to days. *Dementia* - Dementia typically has an **insidious onset** and a **gradual, progressive decline** in cognitive function over months to years. - While the symptoms include memory impairment and functional decline, the rapid onset, association with a depressive episode, and patient's awareness/defensiveness about cognitive issues are more characteristic of pseudodementia. *Both dementia and delirium* - While both conditions cause cognitive impairment, the patient's symptoms do not align with the fluctuating course and acute altered consciousness of delirium, nor the typical insidious progression of true dementia. - The presentation is more consistent with a **depressive pseudo-dementia**, and there's no evidence to suggest co-occurrence of both dementia and delirium.
Explanation: **Continue paroxetine therapy for 2 years** - This patient has experienced **recurrent major depressive episodes**, with two episodes in the past year. Guidelines recommend continuing antidepressant therapy for **1-3 years or indefinitely** after a second or third episode to prevent relapse. - Given his significant improvement and history of recurrent depression, long-term maintenance with paroxetine is the most appropriate strategy. *Discontinue paroxetine* - Discontinuing the antidepressant now would significantly increase the risk of a rapid **relapse** of major depressive disorder, especially given his history of multiple episodes. - Antidepressants should not be abruptly stopped once symptoms resolve, particularly in patients with recurrent depression. *Switch from paroxetine to venlafaxine therapy* - There is no indication to switch to venlafaxine, as the patient has responded well to paroxetine and is currently in **remission**. - Switching medications carries the risk of new side effects or a recurrence of depressive symptoms. *Continue paroxetine therapy for 6 months* - While 6 months of continuation therapy is standard after a **first episode** of major depressive disorder, it is insufficient for patients with **recurrent episodes**. - Continuing for only 6 months heightens the risk of relapse for this patient given his history. *Switch from paroxetine to lithium therapy* - Lithium is typically used as a mood stabilizer for **bipolar disorder** or as an augmentation strategy for refractory depression. - There is no evidence in the vignette to suggest bipolar disorder, and the patient has responded well to monotherapy with paroxetine.
Major depressive disorder diagnostic criteria
Practice Questions
Neurobiological basis of depression
Practice Questions
Genetic and environmental risk factors
Practice Questions
Depression with melancholic features
Practice Questions
Depression with atypical features
Practice Questions
Depression with psychotic features
Practice Questions
Seasonal affective disorder
Practice Questions
Postpartum depression
Practice Questions
Treatment-resistant depression
Practice Questions
Pharmacotherapy for depression
Practice Questions
Psychotherapy approaches for depression
Practice Questions
ECT and neuromodulation therapies
Practice Questions
Suicide risk assessment and management
Practice Questions
Get full access to all questions, explanations, and performance tracking.
Start For Free